Join Clinical Trials in New York for Cancer

All Categories Most Often Searched » Cancer » New York

Potential Imaging and Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors

Condition: Pancreatic Neuroendocrine Cancer
Intervention: Other: MRI
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012
Food: A Three-Arm Study Examining Food Insecurity Interventions

Condition: Cancer Patients
Interventions: Behavioral: Food pantry only arm; Behavioral: Food pantry + Food voucher arm; Behavioral: Food pantry + Grocery delivery
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Queens Cancer Center of Queens Hospital; Brooklyn Hospital Center; Lincoln Hospital Center; Ralph Lauren Center for Cancer Care and Prevention
Recruiting - verified May 2012
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Condition: Multiple Myeloma
Interventions: Drug: Placebo; Drug: Dexamethasone; Drug: Bortezomib; Biological: Tabalumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012
An Observational Pilot Study Evaluating The Feasibility of Conducting Genomewide Association Studies Utilizing Subject-Provided Information in Subjects With Metastatic Breast Cancer Treated With Avastin (Bevacizumab)

Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech; 23andMe, Inc.
Recruiting - verified May 2012
Bathing Bundle Regimen in Reducing Gynecological Surgical Site Infection in Patients Undergoing Surgery

Condition: Female Reproductive Cancer
Intervention: Procedure: infection prophylaxis and management
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified May 2012
Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation

Condition: Leukemia
Interventions: Biological: 8 x 10e6 CD34+ cells per kg; Biological: 4 x 10e6 CD34+ cells per kg
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012
Double Cord vs. Haploidentical (BMT CTN #1101)

Conditions: Acute Lymphocytic Leukemia; Acute Myelogenous Leukemia; Burkitt's Lymphoma; Follicular Lymphoma; Hodgkin Lymphoma; Mantle Cell Lymphoma
Interventions: Drug: Biological/Vaccine: Haploidentical BMT; Drug: Double Cord Blood Transplantation
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Not yet recruiting - verified May 2012
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

Condition: Neoplasms, Hematologic
Interventions: Drug: 200 mg LY2784544; Drug: 400 mg LY2784544; Drug: 600 mg LY2784544
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012
Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Other: Neuroimaging & Neuropsychological Evaluation; Other: Neuroimaging & Neuropsychological Evaluation
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University
Recruiting - verified May 2012
Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection

Condition: Liver Cancer
Interventions: Procedure: Standard fluid management; Device: Goal directed fluid therapy with the FloTrac sensor
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012
Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

Condition: Bladder Cancer
Intervention: Drug: Gemcitabine and Cisplatin (DD GC)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Prospective Trial of Two Prone Breast Radiotherapy Techniques With Randomization to Concurrent Versus Weekly Boost

Condition: Breast Cancer
Intervention: Other: Radiation Therapy
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified May 2012
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

Condition: Intraocular Melanoma
Interventions: Drug: vorinostat; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: western blotting; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Safety Study of Topical Compound 31543 (Calcitriol, USP) in Patients Receiving Chemotherapy for Breast Cancer

Conditions: Alopecia; Breast Cancer
Intervention: Drug: compound 31543 Calcitriol
Sponsors: Berg Pharma,LLC; Berg Pharma,LLC
Not yet recruiting - verified April 2012
Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Sunitinib In Patients With Metastatic Renal Cell Carcinoma

Condition: Renal Cancer
Intervention: Drug: 124IcG250
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Wilex
Recruiting - verified April 2012
Head to Head Study Epi proColon and FIT

Condition: Colorectal Cancer
Intervention:
Sponsors: Epigenomics, Inc; Epigenomics, Inc
Recruiting - verified April 2012
Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Condition: Lung Cancer
Intervention: Drug: LDE225, Etoposide and Cisplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified May 2012
Crizotinib and STA-9090 in ALK Positive Lung Cancers

Condition: Advanced Lung Cancer
Intervention: Drug: ganetespib (STA-9090) and crizotinib
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Do Your Genes Put You at a Higher Risk of Developing Mesothelioma

Condition: Mesothelioma
Intervention:
Sponsors: Wake Forest University; Wake Forest University; University of Pennsylvania; Mayo Clinic; New York University School of Medicine; Johns Hopkins University; Mount Sinai School of Medicine; Memorial Sloan-Kettering Cancer Center; Mesothelioma Applied Research Foundation, Inc.
Recruiting - verified May 2012
Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel

Condition: Cancer
Intervention: Drug: SOR-C13
Sponsors: Soricimed Biopharma Inc; Soricimed Biopharma Inc
Not yet recruiting - verified April 2012
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Conditions: Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour
Interventions: Drug: Octreotide; Drug: Octreotide; Drug: 177Lu-DOTA0-Tyr3-Octreotate
Sponsors: Advanced Accelerator Applications; Advanced Accelerator Applications; Pierrel Research Europe GmbH
Not yet recruiting - verified April 2012
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Smal Cell Lung Cancer)

Condition: Small Cell Lung Carcinoma
Interventions: Drug: BAY1000394; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2012
Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus

Conditions: Barrett's Esophagus; Esophageal Neoplasms
Interventions: Device: Radiofrequency Ablation(RFA) by HALO device.; Device: Endoscopic mucosal resection(EMR) by mucosectomy kit.
Sponsors: Kansas City Veteran Affairs Medical Center; Kansas City Veteran Affairs Medical Center; American Society for Gastrointestinal Endoscopy; Cook Incorporated; Washington University School of Medicine; Columbia University; University of Chicago
Recruiting - verified April 2012
The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List

Conditions: Vitamin D Deficiency; Hepatocellular Carcinoma
Interventions: Drug: Vitamin D3 4000 IU; Drug: Vitamin D3 2000 IU
Sponsors: Mount Sinai School of Medicine; Andrea Branch
Recruiting - verified April 2012
Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

Condition: Glioblastoma Multiforme
Interventions: Drug: Lucanthone; Drug: Temozolomide (TMZ); Radiation: Radiation; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified April 2012
Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort

Conditions: Prostate Cancer; Robotic Prostatectomy; Foley Catheter Discomfort
Interventions: Drug: Bupivacaine; Drug: Saline
Sponsors: Columbia University; Columbia University
Recruiting - verified March 2012
Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer

Conditions: Hematuria; Dysuria; Bladder Cancer
Intervention:
Sponsors: Medical Diagnostic Laboratories, LLC; Medical Diagnostic Laboratories, LLC
Recruiting - verified March 2012
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Plasma Cell Neoplasm; Poor Prognosis Metastatic Gestational Trophoblastic Tumor; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Neuroblastoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage II Ovarian Epithelial Cancer; Stage II Ovarian Germ Cell Tumor; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Breast Cancer; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Small Lymphocytic Lymphoma
Interventions: Procedure: management of therapy complications; Procedure: musculoskeletal complications management/prevention
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Not yet recruiting - verified May 2012
Autologous T Cells Expressing Enhanced TCRs Specific for MAGEA3/A6/B18 or NYESO-1/LAGE in Patients With Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Biological: T cells; Biological: T cells
Sponsors: University of Pennsylvania; University of Pennsylvania; Roswell Park Cancer Institute; Adaptimmune Ltd.
Recruiting - verified April 2012
Quality of Life Outcomes Following Minimally Invasive and Open Esophagectomy for Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Behavioral: Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log; Behavioral: Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012
Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: lapatinib ditosylate; Biological: trastuzumab
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Not yet recruiting - verified March 2012
Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Smac mimetic TL32711; Drug: gemcitabine hydrochloride; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: biopsy
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified April 2012
The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Mastectomy Skin Flap Viability

Conditions: Breast Cancer; Breast Reconstruction; Mastectomy
Intervention: Device: Laser-Assisted ICG Dye Angiography (SPY System)
Sponsors: Stony Brook University; Stony Brook University
Recruiting - verified March 2012
Prospective Study of Clinically Nonfunctioning Pituitary Adenomas

Conditions: Pituitary Adenoma; Pituitary Tumor
Intervention:
Sponsors: Columbia University; Columbia University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2012
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

Condition: Adenoid Cystic Carcinoma
Intervention: Drug: AG-013736 (AXITINIB)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Comprehensive Cancer Network; Pfizer
Recruiting - verified March 2012
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: AC regimen; Drug: TAC regimen; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function

Condition: Solid Cancers
Intervention: Drug: Vismodegib
Sponsors: Genentech; Genentech
Not yet recruiting - verified March 2012
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Blastic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; de Novo Myelodysplastic Syndromes; Noncontiguous Stage II Adult Burkitt Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Stage I Adult Burkitt Lymphoma; Stage III Adult Burkitt Lymphoma; Stage IV Adult Burkitt Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: rasburicase; Drug: allopurinol; Drug: rasburicase
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012
Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy

Condition: Esophageal Cancer
Intervention: Device: wireless pulse oximeter (Wipox)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
BKM120 in Metastatic Transitional Cell Carcinoma of the Urothelium

Condition: Metastatic Transitional Cell Carcinoma of the Urothelium
Intervention: Drug: BKM120
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis
Recruiting - verified March 2012
Collection of FUJIFILM's 3Dimensional Mammograms

Condition: Breast Cancer
Interventions: Device: 3Dimensional Mammography; Device: 2D FFDM
Sponsors: Fujifilm Medical Systems USA, Inc.; Fujifilm Medical Systems USA, Inc.
Recruiting - verified March 2012
Degarelix Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer

Conditions: Prostate Cancer; Prostatic Adenocarcinoma
Interventions: Drug: degarelix injection; Drug: degarelix injection
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Ferring Pharmaceuticals
Recruiting - verified April 2012
MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer

Condition: Prostate Cancer
Interventions: Procedure: Core Needle TRUS Needle biopsy (Transrectal ultrasound); Procedure: Core Needle MRI/US image fusion guided needle biopsy
Sponsors: Philips Healthcare; Philips Healthcare
Not yet recruiting - verified May 2012
Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: 89Zr-DFO-huJ591
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University; Broad Institute of MIT and Dana-Farber Cancer Institute of Harvard
Recruiting - verified February 2012
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012
Cryopreservation of Ovarian Tissue

Conditions: Cancer; Risk of Premature Ovarian Failure; Fertility Preservation
Intervention: Procedure: surgery to remove ovaries or high dose chemotherapy
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities

Condition: Breast Cancer
Interventions: Other: Tracking & Feedback; Other: Control
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
Application of High Resolution Diffusion-Weighted MR Imaging Plus Sequence in Head and Neck Cancer

Condition: Head and Neck Cancer
Intervention: Other: MRI scanner with sequence
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012
Doctor-Patient Communication About Colorectal Cancer Screening

Condition: Colorectal Cancer Screening
Intervention: Behavioral: surveys
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Albert Einstein College of Medicine of Yeshiva University; HHC, Gun HIll and Tremont; NYC RING, Director; Virginia Commonwealth University
Not yet recruiting - verified February 2012
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: carfilzomib; Drug: Dexamethasone; Drug: Clarithromycin; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Lenalidomide
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; Onyx Therapeutics, Inc.
Not yet recruiting - verified March 2012
Tobacco Dependence in Breast Cancer Patients Scheduled for Mastectomy/Reconstructive Surgery Trial of Varenicline (Chantix)

Conditions: Breast Cancer; Tobacco Dependence
Interventions: Drug: placebo; Drug: varenicline
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Pfizer
Recruiting - verified February 2012
MRI and Diffusion Tensor Imaging of the Motor and Language Pathways to Optimize Brain Tumor Resection

Condition: Brain Cancer
Intervention: Procedure: preoperative fMRI and DTI with tractography
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012
Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: MDV3100
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified March 2012
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Aplastic Anemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Congenital Amegakaryocytic Thrombocytopenia; Diamond-Blackfan Anemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Paroxysmal Nocturnal Hemoglobinuria; Peripheral T-cell Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Severe Combined Immunodeficiency; Severe Congenital Neutropenia; Shwachman-Diamond Syndrome; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia; Wiskott-Aldrich Syndrome
Interventions: Drug: fludarabine phosphate; Drug: melphalan; Radiation: total-body irradiation; Drug: tacrolimus; Drug: mycophenolate mofetil; Drug: methotrexate; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
Metformin in Children With Relapsed or Refractory Solid Tumors

Conditions: Solid Tumors; Primary Brain Tumors
Interventions: Drug: Vincristine sulfate; Drug: Irinotecan; Drug: Temozolomide; Drug: Metformin
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Pediatric Cancer Foundation
Not yet recruiting - verified April 2012
Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity

Condition: Oropharyngeal Neoplasms
Interventions: Drug: Docetaxel; Drug: Cisplatin; Drug: Flourouracil; Radiation: External beam radiation therapy/ Intensity modulated RT; Drug: Cisplatin; Drug: Carboplatin
Sponsors: North Shore Long Island Jewish Health System; Bhoomi Mehrotra
Recruiting - verified February 2012
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

Condition: Waldenstrom Macroglobulinemia
Interventions: Biological: ofatumumab; Drug: bortezomib; Other: laboratory biomarker analysis
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Comprehensive Cancer Network
Recruiting - verified April 2012
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Dovitinib; Drug: Fulvestrant
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Dose-Escalation Study in Participants With Advanced Cancer

Condition: Advanced Cancer
Intervention: Drug: LY2495655
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified January 2012
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib; Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
EUS-Guided ERCP Multicenter Registry

Conditions: Cholangiocarcinoma; Pancreatic Cancer; Bile Duct Cancer; Biliary Stricture; Biliary Obstruction; Stent Obstruction; Proximal Duct Stricture; Distal Duct Stricture; Ampullary Cancer; Biliary Sphincter Stenosis; Impacted Stones; Chronic Pancreatitis; Peri-ampullary Diverticula; Altered Anatomy
Intervention: Procedure: Endoscopic Ultrasound (EUS) guided Endoscopic retrograde cholangiopancreatography (ERCP)
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified January 2012
A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer

Condition: Colon Cancer
Intervention: Drug: PDT with 5-ALA radiosensitization
Sponsors: Holcombe, Randall F., M.D.; Holcombe, Randall F., M.D.; University of California, Irvine; National Cancer Institute (NCI)
Recruiting - verified January 2012
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Primary Hepatocellular Carcinoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Hormone-resistant Prostate Cancer; Limited Stage Small Cell Lung Cancer; Localized Resectable Adult Primary Liver Cancer; Male Breast Cancer; Mast Cell Sarcoma; Ovarian Sarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Adult Soft Tissue Sarcoma; Recurrent Bladder Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Esophageal Cancer; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Gastric Cancer; Recurrent Kaposi Sarcoma; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Osteosarcoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Prostate Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Small Intestine Leiomyosarcoma; Stage I Colon Cancer; Stage I Rectal Cancer; Stage I Uterine Sarcoma; Stage IA Breast Cancer; Stage IA Gastric Cancer; Stage IA Ovarian Epithelial Cancer; Stage IA Ovarian Germ Cell Tumor; Stage IB Breast Cancer; Stage IB Gastric Cancer; Stage IB Ovarian Epithelial Cancer; Stage IB Ovarian Germ Cell Tumor; Stage IC Ovarian Epithelial Cancer; Stage IC Ovarian Germ Cell Tumor; Stage II Breast Cancer; Stage II Uterine Sarcoma; Stage IIA Colon Cancer; Stage IIA Gastric Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIA Rectal Cancer; Stage IIB Colon Cancer; Stage IIB Esophageal Cancer; Stage IIB Gastric Cancer; Stage IIB Melanoma; Stage IIB Non-small Cell Lung Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIB Rectal Cancer; Stage IIC Colon Cancer; Stage IIC Melanoma; Stage IIC Ovarian Epithelial Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIC Rectal Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Colon Cancer; Stage IIIA Esophageal Cancer; Stage IIIA Gastric Cancer; Stage IIIA Melanoma; Stage IIIA Non-small Cell Lung Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Rectal Cancer; Stage IIIB Breast Cancer; Stage IIIB Colon Cancer; Stage IIIB Esophageal Cancer; Stage IIIB Gastric Cancer; Stage IIIB Melanoma; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Rectal Cancer; Stage IIIC Breast Cancer; Stage IIIC Colon Cancer; Stage IIIC Esophageal Cancer; Stage IIIC Gastric Cancer; Stage IIIC Melanoma; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Rectal Cancer; Stage IV Bladder Cancer; Stage IV Esophageal Cancer; Stage IV Gastric Cancer; Stage IV Melanoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sirolimus; Other: laboratory biomarker analysis; Biological: DEC-205-NY-ESO-1 fusion protein vaccine
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
Afatinib (BIBW 2992) in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

Conditions: Esophageal Cancer; Gastric Cancer
Intervention: Drug: Afatinib (BIBW 2992)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

Condition: Urothelial Carcinoma
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Ipilimumab
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bristol-Myers Squibb
Recruiting - verified March 2012
Attention and Interpretation Modification (AIM) for Fear of Breast Cancer Recurrence: An Intervention Development Study

Condition: Breast Cancer
Intervention: Behavioral: AIM materials and assessments
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Brown University; Weill Medical College of Cornell University
Recruiting - verified March 2012
Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

Condition: Carcinoma, Non-small Cell Lung
Intervention: Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified May 2012
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Drug: veliparib; Genetic: gene expression analysis; Genetic: protein analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: mitoxantrone; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified April 2012
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Condition: Advanced Solid Tumors
Intervention: Drug: MM-151
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified May 2012
Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression

Condition: Oral Cancer
Intervention:
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Condition: Melanoma
Interventions: Biological: Ipilimumab; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery

Conditions: Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
Interventions: Drug: axitinib; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: 3'-deoxy-3'-[18F]fluorothymidine; Procedure: positron emission tomography
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Condition: Malignant Melanoma
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012
Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma

Conditions: Colon Cancer; Rectal Cancer
Intervention:
Sponsors: University of Michigan; University of Michigan; Early Detection Research Network
Recruiting - verified January 2012
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Lenvatinib (E7080)
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Recruiting - verified May 2012
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer.

Condition: Metastatic Breast Cancer
Interventions: Drug: Veliparib; Drug: Temozolomide; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: Abbott; Abbott
Recruiting - verified May 2012
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Conditions: Metastatic Pancreatic Adenocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer
Intervention: Drug: 90Y-hPAM4
Sponsors: Immunomedics, Inc.; Immunomedics, Inc.
Recruiting - verified May 2012
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Condition: Liver Cancer
Interventions: Drug: RO5137382; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia

Conditions: Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma; Burkitts Leukemia/Lymphoma; Chronic Myelogenous Leukemia
Interventions: Drug: CLAG-M; Drug: CLAG-M
Sponsors: New York Medical College; New York Medical College
Recruiting - verified January 2012
International Travel Patterns and Health Preparations of Hematopoietic Stem Cell Transplant Recipients at Memorial Sloan-Kettering Cancer Center

Condition: Hematopoietic Stem Cell Transplant
Intervention: Behavioral: questionnaire
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Cornell Medical College/Department of Public Health /Division of Prevention and Health Behavior
Recruiting - verified January 2012
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Conditions: Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Primary Peritoneal Cavity Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Primary Peritoneal Cavity Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Epithelial Cancer; Stage IIC Primary Peritoneal Cavity Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Primary Peritoneal Cavity Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Primary Peritoneal Cavity Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Primary Peritoneal Cavity Cancer
Interventions: Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; Drug: sirolimus; Other: laboratory biomarker analysis; Biological: sargramostim
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Conditions: Head and Neck Cancer; Kidney Cancer; Liver Cancer; Sarcoma
Interventions: Drug: sorafenib tosylate; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer

Conditions: Breast Cancer; Invasive Adenocarcinoma of the Breast
Interventions: Procedure: Cryoablation; Biological: Ipilimumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

Conditions: Brain Cancer; Brain Stem Glioma
Intervention: Radiation: Radioactive iodine-labeled monoclonal antibody 8H9
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University; Johns Hopkins University School of Medicine (Data analysis only)
Recruiting - verified March 2012
Combination Chemotherapy in Treating Patients With Advanced or Metastatic Esophageal Cancer, Gastric Cancer, or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Interventions: Drug: FOLFOX regimen; Drug: docetaxel; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Everolimus Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (Gastro Intestinal or Lung Origin)

Conditions: Advanced NET of GI Origin; Advanced NET of Lung Origin; Neuroendocrine Tumors
Interventions: Drug: Everolimus; Drug: Everolimus Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)

Condition: Prostate Cancer
Intervention: Drug: PLX3397
Sponsors: Plexxikon; Plexxikon
Recruiting - verified May 2012
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

Condition: Prostate Cancer
Interventions: Dietary Supplement: Se-methyl-seleno-L-cysteine; Dietary Supplement: selenomethionine; Other: placebo
Sponsors: National Cancer Institute (NCI); Robert H. Lurie Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
CBLB502 in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: pharmacogenomic studies; Other: pharmacological study; Other: laboratory biomarker analysis; Drug: toll-like receptor 5 agonist CBLB502
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; Cleveland BioLabs
Recruiting - verified February 2012
Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From A Normal HLA- Compatible Or Partially- Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Conditions: Non-Hodgkin's Lymphoma; Epstein-Barr Virus
Interventions: Biological: EBV-specific T-cells; Biological: EBV-specific T-cells
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component; Recurrent Glioblastoma; Relapsed Glioblastoma
Interventions: Drug: Bevacizumab; Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
Caris Biorepository Research Protocol

Condition: Cancer
Intervention:
Sponsors: Caris Science, Inc.; Caris Science, Inc.
Recruiting - verified February 2012
Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941; Drug: carboplatin; Drug: paclitaxel; Drug: bevacizumab; Drug: Placebo
Sponsors: Genentech; Genentech
Recruiting - verified February 2012
The BEACON Study (Breast Cancer Outcomes With NKTR-102)

Conditions: Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: NKTR-102; Drug: Treatment of Physician's Choice (TPC)
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2012
Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome

Condition: Liver Cancer
Intervention: Other: CT guided thermal ablation
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Southern California- Keck School of Medicine, Los Angles
Recruiting - verified December 2011
Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors

Conditions: Solid Tumors; Bladder Cancer
Interventions: Drug: Gemcitabine + Cisplatin + Dovitinib; Drug: Gemcitabine + Carboplatin + Dovitinib
Sponsors: Mount Sinai School of Medicine; Matthew Galsky; Novartis
Recruiting - verified March 2012
Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for Adenocarcinoma

Condition: Gastric Cancer
Interventions: Procedure: Roux-en-Y pouch reconstruction (RYP); Procedure: conventional Roux-en-Y reconstruction (RYC)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University; McMaster University
Recruiting - verified December 2011
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

Conditions: Neuroblastoma; Sarcoma
Intervention: Drug: Cyclophosphamide, Topotecan, and Bevacizumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech; Children's Mercy Hospital Kansas City; Penn State University; University of Colorado Health Sciences Center and The Children's Hospital; Johns Hopkins Medical Center Sidney Kimmel Comprehensive Cancer Center; Phoenix Children's Hospital Center for Cancer & Blood Disorders; Alberta Children's Hospital; MD Anderson Cancer Center Orlando; M.D. Anderson Cancer Center
Recruiting - verified December 2011
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab; Drug: Aromatase Inhibitor; Drug: Induction Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Conditions: Prostate Cancer Metastatic; Hormone Refractory Prostate Cancer
Interventions: Biological: sipuleucel-T; Drug: abiraterone acetate
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2012
Efficacy & Safety Study of MORAb-004 to Treat Metastatic Colorectal Cancer

Conditions: Metastatic Colorectal Cancer; Colorectal Cancer
Interventions: Drug: MORAb-004; Drug: Placebo
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2012
Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection

Condition: Prostate Cancer
Intervention: Drug: 99mTc-MIP-1404
Sponsors: Molecular Insight Pharmaceuticals, Inc.; Molecular Insight Pharmaceuticals, Inc.
Recruiting - verified April 2012
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

Condition: Pancreatic Cancer
Intervention: Drug: LDE225+gemcitabine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Condition: Prostate Cancer
Interventions: Drug: GDC-0068; Drug: GDC-0980; Drug: placebo; Drug: abiraterone; Drug: prednisone
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: 3-dimensional conformal radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer

Condition: Ovarian Cancer Recurrent
Interventions: Drug: EP-100; Drug: Paclitaxel
Sponsors: Esperance Pharmaceuticals Inc; Esperance Pharmaceuticals Inc
Recruiting - verified May 2012
Patient Factors Impacting Adherence to Oral Chemotherapy

Conditions: Breast Cancer; Gastrointestinal Cancer
Intervention: Behavioral: questionnaire and interview
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
VOICE: Cancer Communication Study

Condition: Cancer
Intervention: Behavioral: Coaching
Sponsors: University of Rochester; University of Rochester; National Cancer Institute (NCI)
Recruiting - verified December 2011
Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging

Conditions: Breast Cancer; Colon Cancer; Lung Cancer; Neuroblastoma; Testicular Cancer
Interventions: Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: PI3K inhibitor BKM120; Drug: docetaxel; Other: pharmacological study; Other: pharmacogenomic studies; Genetic: DNA analysis; Other: questionnaire administration; Genetic: polymorphism analysis; Genetic: mutation analysis
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified May 2012
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Ganetespib Dexamethasone; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Emory University; Emory University; Multiple Myeloma Research Consortium
Recruiting - verified March 2012
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Condition: Smoldering Multiple Myeloma
Interventions: Drug: Siltuximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified February 2012
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer

Condition: Colorectal Cancer Metastatic
Intervention: Device: TheraSphere
Sponsors: Nordion (Canada) Inc.; Nordion (Canada) Inc.
Recruiting - verified May 2012
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified April 2012
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Condition: Colorectal Cancer
Interventions: Drug: Tivozanib; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; AVEO Pharmaceuticals, Inc.
Recruiting - verified March 2012
NBRST: Prospective Neo-adjuvant REGISTRY Trial

Condition: Breast Cancer
Interventions: Device: MammaPrint; Device: BluePrint; Device: TargetPrint; Device: TheraPrint
Sponsors: Agendia; Agendia
Recruiting - verified April 2012
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): Pilot Study

Conditions: Infection; Bone Neoplasms
Intervention: Procedure: Prophylactic Cefazolin Antibiotic Regimen
Sponsors: McMaster University; Michelle Ghert
Not yet recruiting - verified April 2012
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: PCI-32765
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified May 2012
Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer

Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Behavioral: geriatric assessment and telephone call from nurse; Other: geriatric assessment and no call from nurse
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Neuropsychologic and Electrophysiological Features of Cancer-Related Cognitive Side Effects in Racial and Ethnic Minority Breast Cancer Patients

Condition: Breast Cancer
Interventions: Other: EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire; Other: EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire; Other: EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; The City College of New York; Ralph Lauren Center for Cancer Care and Prevention; Lincoln Hospital
Recruiting - verified November 2011
Changes in Brain Structure Related to Systemic Chemotherapy Treatment: A Prospective Study in Individuals Diagnosed With Non-small Cell Lung Cancer Utilizing High-resolution Structural Magnetic Resonance Imaging

Condition: Non-small Cell Lung Cancer
Interventions: Other: MRI Screening Form, MRI, Demographic / Medical Data form; Other: MRI Screening Form, MRI. Demographic / Medical Data
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of BMS-663513 in Subjects With Advanced and/or Metastatic Solid Tumors

Condition: Cancer - Solid Tumors
Interventions: Drug: BMS-663513 (Anti-CD137); Drug: BMS-663513 (Anti-CD137); Drug: BMS-663513 (Anti-CD137)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2011
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

Condition: Lung Cancer - Non Small Cell
Interventions: Biological: Ipilimumab; Biological: Pemetrexed
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified February 2012
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Condition: Pancreatic Cancer
Interventions: Drug: GS-6624; Drug: GS-6624; Drug: Placebo; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: GS-6624
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012
Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation

Condition: Melanoma
Intervention: Drug: vemurafenib
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified May 2012
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: pazopanib hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Condition: Bladder Cancer
Interventions: Drug: Apaziquone; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; Allergan
Recruiting - verified May 2012
Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma

Condition: Pancreatic Adenocarcinoma
Intervention: Other: Blood draw
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; CellPath Therapeutics, Inc
Recruiting - verified December 2011
Improving a Bayesian Model's Survival Estimates in Patients Needing Surgery for Bone Metastases

Condition: Bone Metastases
Intervention: Other: blood sampling, the SF-36 questionnaire
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Naval Medical Research Center
Recruiting - verified November 2011
Understanding Symptom Recognition and Treatment Decision-making in Hispanic/Latino Lung Cancer Patients

Condition: Lung Cancer
Intervention: Behavioral: semi-structured interviews
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; The Sophie Davis School of Biomedical Education The City College of New York; CUNY
Recruiting - verified January 2012
Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence

Condition: Glioblastoma Multiforme
Intervention: Drug: Avastin
Sponsors: Brain & Spine Surgeons of New York; Brain & Spine Surgeons of New York
Recruiting - verified February 2012
A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

Condition: 3rd Line GIST
Intervention: Drug: STI571 + BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012
Phase 2 Study of Thermodox as Adjuvant Therapy With Radiofrequency Ablation (RFA) in Treatment of Colorectal Liver Metastases (CRLM)

Condition: Colon Cancer Liver Metastasis
Interventions: Drug: Lyso-Thermosensitive Liposomal Doxorubicin; Other: 5% Dextrose Solution
Sponsors: Celsion; Celsion
Recruiting - verified March 2012
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults

Condition: Breast Cancer
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Institutes of Health (NIH); National Institute on Aging (NIA)
Recruiting - verified November 2011
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: sunitinib malate; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance After Autologous Stem Cell Transplantation

Condition: Multiple Myeloma
Intervention: Drug: lenalidomide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Montefiore Medical Center; State University of New York - Downstate Medical Center; NYU MEDICAL CENTER; University of Rochester; Weill Medical College of Cornell University; Stamford Hospital
Recruiting - verified March 2012
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: blinatumomab
Sponsors: Micromet GmbH; Micromet GmbH
Recruiting - verified February 2012
Adverse Event Toxicity Intervention Study To Evaluate The Effect Of Prophylactic Treatment And An Interrupted Dosing Schedule On The Incidence Of Adverse Events In Patients Treated With Dacomitinib (PF-00299804)

Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: PF-00299804 Plus Blinded Doxycycline Placebo; Drug: PF-00299804 Plus Blinded Doxycycline; Drug: PF-00299804
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Comparing Robotics and Laparoscopy With Laparotomy/Open Surgery for Endometrial Cancer

Condition: Cancer of the Endometrium
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Not yet recruiting - verified November 2011
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab [MetMAb]; Drug: erlotinib [Tarceva]; Drug: Placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified January 2012
Feasibility and Psychometric Properties of Paper vs. Web vs. Automated Telephone Administration of Patient Reported Outcome Surveys

Conditions: Colon Cancer; Rectal Cancer
Interventions: Behavioral: surveys; Behavioral: surveys; Behavioral: surveys; Behavioral: Surveys
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
BMS-936558 (MDX-1106) In Combination With Sunitinib or Pazopanib in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Conditions: Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Drug: Sunitinib; Drug: Pazopanib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Company, Ltd.
Recruiting - verified March 2012
Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma

Condition: Melanoma
Intervention: Biological: Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Rockefeller University
Recruiting - verified March 2012
Study of ACE-041 in Patients With Squamous Cell Carcinoma of the Head and Neck

Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Biological: ACE-041
Sponsors: Acceleron Pharma, Inc.; Acceleron Pharma, Inc.
Recruiting - verified March 2012
Optical Imaging of Head and Neck Cancer

Conditions: Squamous Cell Carcinoma; Neoplasia; Head and Neck Cancer
Interventions: Drug: Proflavine; Device: High Resolution Microendoscope; Device: Identafi 3000
Sponsors: Mount Sinai School of Medicine; Sharmila Anandasabapathy; Mount Sinai School of Medicine; William Marsh Rice University
Recruiting - verified December 2011
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

Condition: Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: PEGPH20+ gemcitabine
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified March 2012
A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Condition: Endometrial Carcinoma
Intervention: Drug: GDC-0980
Sponsors: Genentech; Genentech
Recruiting - verified October 2011
Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls

Condition: Germ Cell Cancer
Interventions: Other: Endo-PAT2000 testing; Other: Endo-PAT2000 testing
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Eribulin; Drug: TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)

Condition: Renal Cancer
Intervention: Drug: BEZ235
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis
Recruiting - verified January 2012
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified October 2011
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease

Conditions: Multiple Myeloma; Non-hodgkin's Lymphoma; Hodgkin's Disease
Intervention: Drug: TG-0054
Sponsors: TaiGen Biotechnology Co., Ltd.; TaiGen Biotechnology Co., Ltd.
Not yet recruiting - verified October 2011
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Conditions: Urologic Neoplasms; Metastatic Bladder Cancer; Urinary Tract Neoplasms
Interventions: Drug: OGX-427 600 mg; Drug: OGX-427 1000 mg; Drug: Placebo
Sponsors: OncoGenex Technologies; OncoGenex Technologies; OncoGenex Pharmaceuticals; PRA International
Recruiting - verified May 2012
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

Condition: Solid Tumors
Interventions: Drug: MM-121 (SAR256212) plus Gemcitabine; Drug: MM-121 (SAR256212) plus Carboplatin; Drug: MM-121 (SAR256212) plus Pemetrexed; Drug: MM-121 (SAR256212) plus Cabazitaxel
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis US, Inc.
Recruiting - verified January 2012
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile

Condition: Multiple Myeloma
Intervention:
Sponsors: Multiple Myeloma Research Foundation; Multiple Myeloma Research Foundation; Translational Genomics Research Institute, Phoenix, Arizona.; Spectrum Health Hospitals; Van Andel Research Institute; Quintiles
Recruiting - verified May 2012
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

Conditions: Sarcoma; Wilm's Tumor; Lymphoma; Neuroblastoma
Intervention: Drug: Ipilimumab(anti-CTLA-4 antibody)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

Condition: Lung Cancer
Interventions: Drug: pemetrexed plus cisplatin; Drug: vinorelbine and docetaxel
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Eli Lilly and Company
Recruiting - verified January 2012
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Conditions: Advanced Solid Tumors; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma
Intervention: Drug: RAD001 + BEZ235
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Conditions: Breast Neoplasms; Neoplasm Metastasis
Interventions: Drug: afatinib; Drug: afatinib; Drug: Vinorelbine; Drug: Investigator's choice of treatment
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma
Intervention: Procedure: Acute Normovolemic Hemodilution
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Condition: Smoldering Multiple Myeloma
Intervention: Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Conditions: Estrogen Receptor Positive Tumor; Breast Cancer
Intervention: Drug: E7389 (eribulin mesylate) and capecitabine
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: AdV-tk + valacyclovir; Biological: Placebo + valacyclovir
Sponsors: Advantagene, Inc.; Advantagene, Inc.
Recruiting - verified May 2012
Multi-arm Study of BMS-936558 in Combination With 3 Platinum-based Doublet Chemotherapy Regimens in Subjects With Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: Gemcitabine; Drug: Cisplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012
Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Condition: Cancer
Intervention: Behavioral: questionnaire administration followed by cognitive interviews
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Ralph Lauren Center for Cancer Care and Prevention; M.D. Anderson Cancer Center; St. Joseph’s Hospital, Los Angeles; Hektoen Stroger Hospital; University of Miami; National Cancer Institute (NCI); FACITtrans, LLC
Recruiting - verified April 2012
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Condition: Soft Tissue Sarcoma
Interventions: Drug: TH-302 in Combination with Doxorubicin; Drug: Doxorubicin
Sponsors: Threshold Pharmaceuticals; Threshold Pharmaceuticals; Sarcoma Alliance for Research through Collaboration (SARC)
Recruiting - verified March 2012
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Condition: Myeloma
Interventions: Drug: Pomalidomide; Drug: Dexamethasone; Drug: Cyclophosphamide
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified May 2012
A Study to Evaluate the Use of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Cyclophosphamide; Drug: Velcade; Drug: Chloroquine
Sponsors: New York University School of Medicine; New York University School of Medicine; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Condition: Uveal Melanoma
Intervention: Drug: AEB071
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: Ramucirumab (IMC-1121B); Drug: Eribulin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Conditions: Melanoma; Malignant Melanoma
Intervention: Drug: CT-011
Sponsors: CureTech Ltd; CureTech Ltd
Recruiting - verified January 2012
Patient Controlled Tissue Expansion for Breast Reconstruction

Condition: Breast Cancer
Interventions: Device: AeroForm Patient Controlled Tissue Expander; Procedure: Implantation of Saline Tissue Expander
Sponsors: AirXpanders, Inc.; AirXpanders, Inc.
Recruiting - verified April 2012
The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor; Secondary Malignant Neoplasm of Liver
Intervention: Other: magnetic resonance imaging (MRI)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011
Study of Ruxolitinib in Pancreatic Cancer Patients

Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Number 1 - Capecitabine and ruxolitinib; Drug: Number 2 - Capecitabine and placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2012
Toll-like Receptor (TLR) 7 Agonist and Radiotherapy for Breast Cancer With Skin Metastases

Conditions: Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer
Interventions: Radiation: Radiation; Drug: Imiquimod
Sponsors: New York University School of Medicine; New York University School of Medicine; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: anti-cancer therapy
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

Condition: Neuroblastoma
Intervention: Biological: Humanized 3F8 Monoclonal Antibody (Hu3F8)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Conditions: Sarcoma; Leiomyosarcoma; Malignant Peripheral Nerve Sheath Tumor; Malignant Fibrous; Histiocytoma/Undifferentiated Pleomorphic Sarcoma
Intervention: Drug: Gemcitabine and Docetaxel in Combination with Pazopanib
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Comprehensive Cancer Network
Recruiting - verified April 2012
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Sponsors: GP-Pharm; GP-Pharm
Recruiting - verified March 2012
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

Conditions: Advanced Solid Tumors; Excluding Breast Cancer
Intervention: Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

Conditions: Cervical Cancer; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Sexuality and Reproductive Issues
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cancer Vaccines CRS-207 and GVAX Pancreas for Metastatic Pancreatic Adenocarcinoma

Condition: Pancreatic Cancer
Interventions: Drug: GVAX Pancreas, Cyclophosphamide and CRS-207; Drug: GVAX Pancreas and Cyclophosphamide
Sponsors: Aduro BioTech, Inc.; Aduro BioTech, Inc.; Johns Hopkins University
Recruiting - verified May 2012
Phase 1-2 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Biological: DPX-Survivac; Drug: low dose cyclophosphamide (oral)
Sponsors: ImmunoVaccine Technologies, Inc.; ImmunoVaccine Technologies, Inc.
Recruiting - verified December 2011
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
Sponsors: Progenics Pharmaceuticals, Inc.; Progenics Pharmaceuticals, Inc.
Recruiting - verified August 2011
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
Sponsors: Progenics Pharmaceuticals, Inc.; Progenics Pharmaceuticals, Inc.
Recruiting - verified August 2011
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

Condition: Neurofibromatosis Type II
Intervention: Drug: Everolimus (RAD001) , Afinitor®
Sponsors: New York University School of Medicine; New York University School of Medicine; Novartis Pharmaceuticals; The Children's Tumor Foundation
Recruiting - verified January 2012
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

Conditions: Prostatic Neoplasm; Prostate Cancer; Prostatic Adenocarcinoma
Interventions: Biological: sipuleucel-T; Drug: leuprolide acetate
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2012
Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant

Condition: Multiple Myeloma
Intervention: Procedure: Fractionated Stem Cell Infusions
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Condition: Neoplasms
Intervention: Drug: BAY80-6946
Sponsors: Bayer; Bayer
Recruiting - verified May 2012
Cook for Your Life

Condition: Breast Cancer
Interventions: Other: Arm A; Behavioral: Arm B
Sponsors: Columbia University; Columbia University; National Cancer Institute (NCI)
Recruiting - verified October 2011
Measuring Patient Expectations for Thyroid Surgery

Condition: Thyroid Cancer
Intervention: Behavioral: patient interviews
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Vitamin D and Physical Activity on Bone Health

Conditions: Bone Metabolism Biomarkers; Bone Mineral Density; Physical Fitness
Interventions: Drug: Vitamin D3; Behavioral: Home-Based Exercise
Sponsors: University of Rochester; University of Rochester
Not yet recruiting - verified August 2011
Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma

Condition: Pancreas, Adenocarcinoma
Intervention: Biological: Biological/Vaccine: BC-819
Sponsors: BioCancell Therapeutics Israel Ltd.; BioCancell Therapeutics Israel Ltd.
Recruiting - verified May 2012
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: Apaziquone; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; Allergan
Recruiting - verified April 2012
An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN™ in Subjects With Cancer Who Also Have Impaired Renal Function

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: E7389; Drug: E7389; Drug: E7389
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified May 2012
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

Conditions: Tumors; Medical Oncology; Neoplasms
Intervention: Drug: AGS-22M6E
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Agensys, Inc.; Seattle Genetics, Inc.
Recruiting - verified March 2012
Allogeneic Transplant in HIV Patients (BMT CTN 0903)

Conditions: Leukemia; Lymphoma; HIV
Interventions: Drug: Fludarabine and Busulfan (Flu/Bu); Drug: Fludarabine and Melphalan (Flu/Mel); Drug: Busulfan and Fludarabine (Bu/Flu); Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI); Drug: Fludarabine; Drug: Busulfan, Fludarabine, Cyclophosphamide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified March 2012
Trial of Modifications to Radical Prostatectomy

Condition: Prostate Cancer
Interventions: Procedure: Fascial suturing; Procedure: Lymph node template
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Faith-based Approaches to Treating Hypertension and Colon Cancer Prevention

Conditions: Blood Pressure; Colorectal Cancer Screening
Interventions: Behavioral: Motivational Interviewing; Behavioral: Patient Navigation
Sponsors: New York University School of Medicine; New York University School of Medicine; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2011
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Condition: Oral Mucositis
Interventions: Biological: ALD518; Drug: 0.9% saline
Sponsors: Alder Biopharmaceuticals, Inc.; Alder Biopharmaceuticals, Inc.
Recruiting - verified April 2012
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

Condition: Advanced Gastric Cancer
Intervention: Drug: AUY922 + Trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Conditions: Prostate Neoplasms; Prostate Cancer
Interventions: Drug: Cohort 4; Drug: Cohort 3; Drug: Cohort 2; Drug: Cohort 1
Sponsors: Cougar Biotechnology, Inc.; Cougar Biotechnology, Inc.
Recruiting - verified May 2012
Partial Breast Irradiation Using Non Invasive Machine for Early Stage Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: Accelerated partial breast irradiation
Sponsors: Brown University; Jaroslaw Hepel; The Miriam Hospital; Rhode Island Hospital
Recruiting - verified May 2012
Electromagnetic Tracking of Devices During Biopsy Procedures

Condition: Liver Tumors
Intervention:
Sponsors: Philips Healthcare; Philips Healthcare
Recruiting - verified May 2012
Fresolimumab and Radiotherapy in Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: fresolimumab (GC1008); Drug: fresolimumab (GC1008); Radiation: Radiation Therapy
Sponsors: New York University School of Medicine; New York University School of Medicine; University of California, Los Angeles
Recruiting - verified May 2012
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)

Condition: Metastatic Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: MEGF0444A; Drug: mFOLFOX6; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011
Ph I/II Ipilimumab Vemurafenib Combo

Condition: Melanoma
Interventions: Drug: Ipilimumab (BMS-734016); Biological: Vemurafenib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Roche-Genentech
Recruiting - verified November 2011
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)

Condition: Renal Cell Carcinoma
Intervention: Drug: everolimus and bevacizumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified March 2012
Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)

Conditions: Esophageal Cancer; Adenocarcinoma
Interventions: Other: serum and tissue mesothelin; Other: serum and tissue mesothelin; Other: serum and tissue mesothelin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies

Conditions: Metastatic Solid Tumor; Lymphoma
Intervention: Drug: PU-H71
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: dasatinib
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified February 2012
Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma

Conditions: Brain Cancer; MALIGNANT GLIOMA; Glioblastoma; Anaplastic Astrocytoma (AA); Anaplastic Oligodendroglioma (AO); Anaplastic Oligo-astrocytoma (AOA); Anaplastic Mixed Gliomas; Malignant Glioma NOS
Intervention: Other: Bevacizumab & stereotactic radiotherapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech; Columbia University; University of California, San Francisco
Recruiting - verified April 2012
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Drug: Lenalidomide; Drug: Lenalidomide
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture

Conditions: Cholangiocarcinoma; Bile Duct Inflammation
Intervention:
Sponsors: Mauna Kea Technologies; Mauna Kea Technologies
Recruiting - verified May 2012
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Condition: Sarcoma, Alveolar Soft Part
Interventions: Drug: Cediranib; Drug: Sunitinib
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)

Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012
Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer

Condition: Breast Cancer
Intervention: Genetic: BRCA testing and questionnaire assessments
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Patients With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy

Conditions: Arthralgia; Breast Cancer; Pain
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others

Conditions: Thyroid Cancer; Papillary Microcarcinoma
Interventions: Behavioral: Focus groups; Behavioral: Focus groups
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer

Condition: Squamous Cell Cancer
Intervention: Drug: proflavine
Sponsors: Anandasabapathy, Sharmila, M.D.; Anandasabapathy, Sharmila, M.D.; William Marsh Rice University
Recruiting - verified June 2011
Endoscopic Multispectral Imaging for the Early Detection of Barrett's Neoplasia

Conditions: Barrett's Esophagus; Intraepithelial Neoplasia
Intervention: Drug: proflavine
Sponsors: Anandasabapathy, Sharmila, M.D.; Anandasabapathy, Sharmila, M.D.; William Marsh Rice University
Recruiting - verified September 2011
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Fatigue; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: modafinil; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified September 2011
Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy

Conditions: Breast Cancer; Lymphoma
Intervention:
Sponsors: University of Rochester; University of Rochester
Recruiting - verified July 2011
MRD Testing Before and After Hematopoietic Cell Transplantation Transplantation for Pediatric Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT); Pediatric Blood and Marrow Transplant Consortium
Recruiting - verified May 2012
A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia -Project 1

Conditions: GERD; Barrett's Esophagus
Interventions: Drug: Fluorescein; Drug: Proflavine hemisulfate
Sponsors: Anandasabapathy, Sharmila, M.D.; Anandasabapathy, Sharmila, M.D.
Recruiting - verified June 2011
The Jewels in Our Genes Study - an African American Family Study of Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: University at Buffalo; University at Buffalo; Susan G. Komen Breast Cancer Foundation
Recruiting - verified June 2011
Evaluation of a Low-Cost High Resolution Microendoscope for the Detection of Lower Gastrointestinal Neoplasia

Conditions: Colon Polyps; Colonic Dysplasia; Anal Dysplasia
Intervention: Drug: Proflavine Hemisulfate
Sponsors: Anandasabapathy, Sharmila, M.D.; Anandasabapathy, Sharmila, M.D.
Recruiting - verified June 2011
Study of Oral MLN9708 in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: MLN9708 + Lenalidomide + Dexamethasone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

Conditions: Light Chain Deposition Disease (LCDD or MIDD); Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD); Monoclonal Immunoglobulin Deposition Disease (MIDD); Amyloidosis
Intervention: Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Conditions: Recurrent Ovarian Cancer; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma
Intervention: Biological: Chimeric monoclonal antibody (TRC105) to CD105
Sponsors: Tracon Pharmaceuticals Inc.; Tracon Pharmaceuticals Inc.
Recruiting - verified March 2012
Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors

Condition: Solid Tumors
Intervention: Drug: Iso-Fludelone
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Pittsburgh
Recruiting - verified March 2012
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Condition: Multiple Myeloma
Intervention: Biological: recMAGE-A3 Protein plus AS15 Adjuvant
Sponsors: Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; GlaxoSmithKline
Recruiting - verified May 2012
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: FOLFIRI regimen; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified December 2011
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Condition: Islet Cell Tumor
Interventions: Drug: Everolimus; Drug: Pasireotide + Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Conditions: Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP

Condition: Lambert Eaton Myasthenic Syndrome (LEMS)
Intervention: Drug: 3,4-diaminopyridine
Sponsors: Columbia University; Columbia University
Available - verified December 2011
Cabazitaxel - PF Induction Chemotherapy

Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cabazitaxel 10mg/m2; Drug: Cabazitaxel 12.5mg/m2; Drug: Experimental: Cabazitaxel 15mg/m2; Drug: Experimental: Cabazitaxel 17.5mg/m2; Drug: Cabazitaxel 20mg/m2
Sponsors: Mount Sinai School of Medicine; Krzysztof Misiukiewicz; Sanofi-Aventis; Mount Sinai School of Medicine
Recruiting - verified November 2011
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Leukemias and Related Disorders

Conditions: Cancer; Hematologic Malignancies; Leukemia; Myeloid Leukemia
Interventions: Drug: Arm 1- Dose Escalation; Drug: Arm 2- Dose Expansion
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor

Condition: Ductal Carcinoma in Situ
Intervention: Drug: SOM 230 / Pasireotide
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified April 2012
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Condition: Lambert Eaton Myasthenic Syndrome
Interventions: Drug: Amifampridine Phosphate; Drug: Placebo
Sponsors: BioMarin Pharmaceutical; BioMarin Pharmaceutical
Recruiting - verified May 2012
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma

Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma
Interventions: Drug: Bevacizumab and Carboplatin; Drug: Bevacizumab and Carboplatin
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified December 2011
Bortezomib and Sorafenib Tosylate in Patients With Newly Diagnosed Acute Myeloid Leukemia With or Without Mutations

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: paclitaxel; Other: pharmacological study; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified May 2012
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Condition: Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); University of Pittsburgh; National Cancer Institute (NCI)
Recruiting - verified January 2012
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

Conditions: Solid Tumor; Colorectal Cancer; Endometrial Cancer
Intervention: Drug: DS-7423
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified March 2012
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012
Trial of Radiation Therapy "Sandwiched" Between Chemotherapy to Treat Uterine Carcinosarcoma

Condition: Uterine Carcinosarcoma
Intervention: Drug: Paclitaxel, Carboplatin and Radiation
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified June 2011
Levofloxacin in Preventing Infection in Young Patients Receiving Chemotherapy For Acute Leukemia or Undergoing Stem Cell Transplantation

Conditions: Bacterial Infection; Leukemia; Musculoskeletal Complications; Neutropenia
Interventions: Drug: levofloxacin; Procedure: standard follow-up care
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: IPI 504 plus Docetaxel; Drug: Placebo plus Docetaxel
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Recruiting - verified February 2012
National Marrow Donor Program Long-Term Donor Follow-Up

Condition: Hematologic Neoplasms
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified June 2011
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Conditions: Pain; Advanced Cancer
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified August 2011
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Conditions: Advanced Solid Tumors,; Selected Solid Tumors
Intervention: Drug: BKM120 + MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: ON 01910.Na; Drug: Gemcitabine; Drug: Gemcitabine
Sponsors: Onconova Therapeutics, Inc.; Onconova Therapeutics, Inc.; Academic Oncology Gastrointestinal Cancer Consortium (AGICC)
Recruiting - verified March 2012
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified February 2012
Emergency Department-Based Palliative Care for Advanced Cancer Patients

Conditions: Advanced Cancer; Metastatic Cancer
Interventions: Other: Early palliative care consultation for ED patients with advanced cancer; Other: Care as usual
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; American Cancer Society
Recruiting - verified February 2012
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy

Conditions: Head and Neck Cancer; Oropharyngeal Cancer; Human Papillomavirus; Squamous Cell Cancer
Intervention:
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine
Recruiting - verified November 2011
A Study of the Safety, Tolerability, and Efficacy of SCH 900353 in Participants With Advanced Solid Tumors (P06203 AM2)

Condition: Tumor, Solid
Intervention: Drug: SCH 900353
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified May 2012
Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer

Condition: Prostate Cancer
Intervention: Other: Prostate Biopsy, Focal Brachytherapy , Assessment of QOL
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Colorado, Denver; M.D. Anderson Cancer Center; North Shore Long Island Jewish Health System
Recruiting - verified April 2012
A Single Center Randomized Controlled Trial Assessing Pain and Quality of Life Following Surgery

Condition: Head and Neck Cancer
Interventions: Other: Flexible Fiber-based CO2 Laser, Quality of Life forms; Other: electrocautery resection and quality of life forms
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; OMNIGUIDE
Recruiting - verified May 2012
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma

Conditions: Multiple Myeloma; Non-Hodgkin's Lymphoma; Glioblastoma Multiforme; Head and Neck Squamous Cell Cancer; Triple Negative Breast Cancer; Hormone Receptor-Positive Breast Cancer; Castration-Resistant Prostate Cancer; Ewing's Family of Sarcomas
Intervention: Drug: CC-115
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

Conditions: Muscle Wasting; Non Small Cell Lung Cancer
Interventions: Drug: GTx-024; Drug: placebo
Sponsors: GTx; GTx; Harrison Clinical Research
Recruiting - verified May 2012
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

Conditions: Muscle Wasting; Non-Small Cell Lung Cancer
Interventions: Drug: GTx-024; Drug: placebo
Sponsors: GTx; GTx; Harrison Clinical Research
Recruiting - verified May 2012
Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer

Conditions: Esophageal Cancer; Malignant Neoplasm of Cardio-esophageal Junction of Stomach
Interventions: Drug: Azacitidine; Drug: Azacitidine; Drug: Azacitidine; Drug: Oxaliplatin; Drug: Oxaliplatin; Drug: Epirubicin; Drug: Epirubicin; Drug: Capecitabine; Drug: Capecitabine
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified June 2011
LLLT Combined With CDT in Breast Cancer-Related Lymphedema

Conditions: Breast Cancer; Lymphedema
Interventions: Device: Low Level Laser Therapy; Device: Low Level Laser
Sponsors: New York University School of Medicine; New York University School of Medicine; Hunter College
Recruiting - verified January 2012
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Conditions: Hematological Malignancies; Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders; Hurler Syndrome (MPS I); Krabbe Disease (Globoid Leukodystrophy); X-linked Adrenoleukodystrophy; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified April 2012
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma

Condition: Mesothelioma
Interventions: Behavioral: Questionnaires & online virtual support group; Behavioral: Questionnaires & online virtual support group
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: azacitidine; Drug: entinostat; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012
Higher-Dose Radiation Therapy or Standard Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid

Condition: Lung Cancer
Intervention: Biological: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Conditions: B Cell Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia
Intervention: Drug: AVL-292
Sponsors: Avila Therapeutics; Avila Therapeutics; The Leukemia and Lymphoma Society
Recruiting - verified May 2011
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Onyx Pharmaceuticals
Recruiting - verified March 2012
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Condition: Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Biological: BMS-936558; Biological: BMS-936558
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Condition: Urothelial Carcinoma
Interventions: Biological: DN24-02; Other: Standard of Care
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2012
Acupressure in Controlling Nausea in Young Patients With Central Nervous System or Solid Tumors Receiving Cisplatin-Containing Chemotherapy

Conditions: Brain and Central Nervous System Tumors; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Procedure: acupressure therapy; Procedure: sham intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011
Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

Condition: Rectal Cancer
Interventions: Drug: Rifaximin; Drug: Placebo
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma

Condition: Recurrent Glioblastoma
Intervention: Drug: PLX3397
Sponsors: Plexxikon; Plexxikon
Recruiting - verified May 2012
MaxAn Post Market Surveillance Validation

Conditions: DDD; Deformity; Tumor; Fracture
Intervention:
Sponsors: Biomet, Inc.; Biomet, Inc.
Recruiting - verified February 2012
Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy

Conditions: Breast Cancer; Colon Cancer; Bladder Cancer
Interventions: Drug: Glycosylated Recombinant Human Interleukin-7; Biological: Diphtheria-Tetanus Vaccine; Biological: Polio Vaccine; Biological: Pneumaococcal Vaccine; Biological: Hepatitis A Vaccine; Biological: Hepatitis B Vaccine; Biological: Influenza Vaccine; Biological: PhiX 174
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia

Condition: Chemotherapy-Induced Thrombocytopenia
Intervention: Drug: ONO-7746
Sponsors: Ono Pharma; Ono Pharma
Recruiting - verified April 2012
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2012
Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

Condition: Metastatic Urothelial Carcinoma
Intervention: Drug: Lenalidomide
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; Celgene Corporation
Recruiting - verified October 2011
A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer

Condition: Prostatic Neoplasm
Intervention: Drug: EZN-4176
Sponsors: Enzon Pharmaceuticals, Inc.; Enzon Pharmaceuticals, Inc.
Recruiting - verified February 2012
Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Conditions: Pain; Advanced Cancer
Intervention: Drug: Sativex®
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified April 2011
ARCHER 1009 : A Study Of PF-00299804 (Dacomitinib) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib (PF-00299804); Drug: Active Comparator (erlotinib)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma

Condition: Glioblastoma
Interventions: Drug: BKM120; Procedure: Surgery
Sponsors: Dana-Farber Cancer Institute; Patrick Y. Wen, MD; Brigham and Women's Hospital; Massachusetts General Hospital; Novartis Pharmaceuticals; M.D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; University of California, San Francisco; University of California, Los Angeles
Recruiting - verified February 2012
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer

Condition: Hepatocellular Carcinoma
Interventions: Device: HepaSphere/QuadraSphere Microspheres; Procedure: PVA, lipiodol, doxorubicin
Sponsors: Merit Medical Systems, Inc.; Merit Medical Systems, Inc.
Recruiting - verified January 2012
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011
A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations

Conditions: Non-Small Cell Lung Cancer; Cancer
Intervention: Drug: GSK2118436
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Drug: FOLFOX regimen; Drug: carboplatin; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

Conditions: Multiple Myeloma; Renal Insufficiency
Interventions: Drug: BHQ880; Drug: BHQ990
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

Condition: Bladder Cancer
Intervention: Drug: Amrubicin
Sponsors: Mount Sinai School of Medicine; Matthew Galsky; Celgene Corporation
Recruiting - verified October 2011
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: hu14.18-IL2 fusion protein; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Genetic: polymorphism analysis; Other: immunologic technique; Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Advanced Lymphoma, Multiple Myeloma, or Solid Tumors

Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: TRC105
Sponsors: Tracon Pharmaceuticals Inc.; Tracon Pharmaceuticals Inc.; Roswell Park Cancer Institute; Department of Defense
Recruiting - verified March 2012
A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V/F-TRICOM + GM-CSF; Biological: PROSTVAC-V/F-TRICOM + GM-CSF placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified January 2012
Trial of Individual Psychosocial Interventions for Cancer Patients

Condition: Stage IV Solid Tumor Diseases
Interventions: Behavioral: Individual Meaning-Centered Psychotherapy (IMCP); Behavioral: standard Individual Supportive Psychotherapy (ISP); Behavioral: enhanced usual care (EUC)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Condition: Soft Tissue Sarcoma
Interventions: Drug: Eribulin mesylate 1.4 mg/m2 intravenous; Drug: Dacarbazine of 850 mg/m2, or 1,000 mg/m2, or 1,200 mg/m2 IV
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified May 2012
Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

Condition: Her2normal
Intervention: Drug: eribulin mesylate
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified February 2012
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Condition: Basal Cell Carcinoma
Intervention: Drug: LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

Conditions: Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood; Hodgkin's Disease; Non-Hodgkin's Lymphoma
Interventions: Drug: Panobinostat; Drug: Cytarabine; Drug: Panobinostat
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Novartis
Recruiting - verified November 2011
Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium

Conditions: Squamous Cell Carcinoma of the Oral Cavity; Oropharynx; Larynx; Hypopharynx
Intervention:
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; William Marsh Rice University
Recruiting - verified April 2012
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

Condition: Melanoma
Intervention: Drug: Ipilimumab, Melphalan and Dactinomycin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb
Recruiting - verified November 2011
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

Condition: Thyroid Cancer
Interventions: Drug: lenvatinib 24 mg administered orally, once a day; Drug: Placebo 24mg administered orally, once a day
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

Conditions: Locally Advanced Malignant Neoplasm; Malignant Solid Tumour
Intervention: Biological: ALT-836 in combination with gemcitabine
Sponsors: Altor Bioscience Corporation; Altor Bioscience Corporation
Recruiting - verified September 2011
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Interventions: Drug: panitumumab; Drug: Randomization to No Panitumumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Amgen
Recruiting - verified March 2012
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Bendamustine; Drug: Bortezomib
Sponsors: New York University School of Medicine; New York University School of Medicine; Cephalon
Recruiting - verified March 2012
Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time

Conditions: Oropharyngeal Cancer; Human Papillomavirus
Intervention:
Sponsors: Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; Mount Sinai School of Medicine; Oregon Health and Science University; Dana-Farber Cancer Institute; Johns Hopkins Hospital (JHH)
Recruiting - verified May 2012
Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: degarelix; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: orchiectomy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2012
Monitoring Minimal Residual Disease Following Treatment of Patients With Acute Myeloid Leukemia (AML) or High Grade Myelodysplastic Syndrome (MDS)

Conditions: Acute Myeloid Leukemia; High Grade Myelodysplastic Syndrome
Intervention:
Sponsors: University of Rochester; University of Rochester; Ohio State University; Rochester General Hospital
Recruiting - verified November 2011
MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: Akt inhibitor MK2206; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Dana-Farber Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2011
Imexon for Relapsed Follicular and Aggressive Lymphomas

Conditions: Follicular Lymphoma; Diffuse Large B Cell Lymphoma; Mantle Cell Lymphoma; Burkitt's Lymphoma
Intervention: Drug: Imexon
Sponsors: University of Rochester; University of Rochester; University of Arizona
Recruiting - verified June 2011
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified March 2012
ABT-888 With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low-Grade Non-Hodgkin's Lymphoma

Conditions: Ovarian; Primary Peritoneal; Serous Carcinoma; Triple-Negative Breast; Fallopian Tube
Interventions: Drug: ABT-888 with Cyclophospharmide; Drug: Cyclophosphamide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: PF-05082566; Drug: rituximab; Drug: PF-05082566
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

Condition: Conventional Chondrosarcoma
Interventions: Drug: IPI-926; Drug: Placebo Arm
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Recruiting - verified May 2012
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Drug: cisplatin
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy

Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Pharmacokinetic, Safety and Tolerability Study of Paclitaxel Injection Concentrate for Nano-dispersion Administered Weekly

Condition: Solid Tumor in Advanced Stage
Intervention: Drug: Paclitaxel Injection Concentrate for Nanodispersion
Sponsors: Sun Pharma Advanced Research Company Limited; Sun Pharma Advanced Research Company Limited
Recruiting - verified August 2011
Pharmacokinetic and Safety Study of Paclitaxel Injection Concentrate for Nano-dispersion Alone and in Combination With Carboplatin

Condition: Solid Tumor in Advanced Stage
Intervention: Drug: Paclitaxel Injection Concentrate for Nanodispersion
Sponsors: Sun Pharma Advanced Research Company Limited; Sun Pharma Advanced Research Company Limited
Recruiting - verified August 2011
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: ACY-1215
Sponsors: Acetylon Pharmaceuticals Incorporated; Acetylon Pharmaceuticals Incorporated; The Leukemia and Lymphoma Society
Recruiting - verified April 2012
Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer

Conditions: Cholangiocarcinoma; Pancreatic Cancer
Intervention: Device: Endoscopic bipolar radiofrequency probe (ENDOHPB)
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; EMcision Limited
Recruiting - verified January 2012
Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus

Condition: Lung Cancer
Intervention: Genetic: obtain tissue specimens
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus

Condition: Esophageal Cancer
Intervention: Device: HANAROSTENT TM covered Esophageal Stent
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; M.I.Tech Co., Ltd.
Recruiting - verified January 2012
Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

Condition: Pancreatic Cancer
Interventions: Biological: ganitumab; Drug: capecitabine; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

Condition: Cervical Intraepithelial Neoplasia
Interventions: Biological: VGX 3100; Biological: Placebo
Sponsors: Inovio Pharmaceuticals; Inovio Pharmaceuticals
Recruiting - verified May 2012
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors

Condition: Solid Tumors
Interventions: Drug: BKM120 days 1 - 21 plus paclitaxel + carboplatin; Drug: BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified February 2012
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Condition: HER-2 Gene Amplification
Interventions: Drug: Cisplatin, Capecitabine, Trastuzumab and MM-111; Drug: Lapatinib, Trastuzumab and MM-111; Drug: Paclitaxel, Trastuzumab and MM-111
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified March 2012
Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI

Condition: Breast Cancer
Intervention: Other: MRI
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: BKM120 or Docetaxel; Drug: BKM120 or Docetaxel or Pemetrexed
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: intraperitoneal chemotherapy; Genetic: gene expression analysis; Genetic: protein analysis; Other: flow cytometry; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
Carboplatin and Bevacizumab for Recurrent Ependymoma

Conditions: Brain Tumor; Spinal Tumor; Glial Tumour of Brain; Ependymal Tumour of Brain; Spinal Cord Ependymoma; Anaplastic Ependymoma
Interventions: Drug: Bevacizumab; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; CERN Foundation - Collaborative Ependymoma Research Network
Recruiting - verified February 2012
VTX-2337 and Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: TLR8 agonist VTX-2337; Drug: pegylated liposomal doxorubicin hydrochloride; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Tesetaxel
Sponsors: Genta Incorporated; Genta Incorporated
Recruiting - verified March 2012
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

Condition: Cancer, Solid Tumor
Interventions: Drug: MK-3475 1 mg/kg; Drug: MK-3475 3 mg/kg; Drug: MK-3475 10 mg/kg; Drug: MK-3475 MEL; Drug: MK-3475 NSCLC
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012
Effects of High Dose Calcitriol in Breast Cancer Patients

Condition: Breast Cancer
Intervention: Drug: Calcitriol
Sponsors: University of Rochester; University of Rochester
Recruiting - verified August 2011
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

Conditions: Solid Tumors; Relapsed/Refractory Sarcomas
Intervention: Drug: Vorinostat and Etoposide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Merck; Phoenix Children's Hospital; Penn State Children's Hospital; Johns Hopkins University; Sidney Kimmel Comprehensive Cancer Center; Children's Hospital Colorado; University of Florida; Alberta Children's Hospital; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; Children's Mercy Hospital & Clinics; All Children's Hospital; Arnold Palmer Hospital for Children/MD Anderson Cancer Center Orlando
Recruiting - verified February 2012
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors or Advanced Pancreatic Cancer

Conditions: Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dovitinib lactate; Drug: gemcitabine hydrochloride; Drug: capecitabine; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: pharmacological study
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Trial of TBL-12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma

Condition: Myeloma
Intervention: Drug: TBL-12
Sponsors: New York University School of Medicine; New York University School of Medicine; Unicorn Pacific Corporation
Recruiting - verified May 2012
Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer

Conditions: Basal Cell Carcinoma of the Skin; Pain; Recurrent Skin Cancer
Interventions: Drug: methyl-5-aminolevulinate hydrochloride cream; Drug: photodynamic therapy; Procedure: laser therapy
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Condition: Prostatic Neoplasms
Interventions: Drug: MDV3100; Drug: Bicalutamide
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Medivation, Inc.
Recruiting - verified March 2012
Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Carboplatin; Radiation: 3D-RT or IMRT
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified March 2012
A Study of RO5185426 (Vemurafenib) in Patients With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

Condition: Neoplasms
Intervention: Drug: RO5185426
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32

Conditions: Breast Cancer; Depression; Fatigue; Sleep Disorders
Interventions: Drug: metformin hydrochloride; Genetic: DNA analysis; Genetic: RNA analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population

Condition: Lung Cancer, Small Cell
Interventions: Drug: pazopanib; Drug: pemetrexed
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients

Condition: Oral Mucositis
Interventions: Device: MuGard; Device: Control Rinse
Sponsors: Access Pharmaceuticals, Inc.; Access Pharmaceuticals, Inc.
Recruiting - verified April 2012
MK-2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Intervention: Drug: MK-2206
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified February 2012
Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Condition: Lung Cancer - Non Small Cell
Interventions: Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

Condition: Tumors Characterized by Genetic Abnormalities of ALK
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: ICM plus Olaparib; Drug: ICM without Olaparib
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2011
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: DSTP3086S
Sponsors: Genentech; Genentech
Recruiting - verified October 2011
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Condition: Cervical Cancer
Interventions: Drug: cisplatin; Drug: paclitaxel; Drug: veliparib; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

Condition: Smoldering Multiple Myeloma
Intervention: Drug: BHQ880
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer

Conditions: Cognitive/Functional Effects; Colorectal Cancer; Neurotoxicity
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified February 2012
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Conditions: Carcinoma of Urinary Tract; Urethral Carcinoma; Carcinoma of Ureter; Carcinoma of Renal Pelvis
Interventions: Drug: Docetaxel; Biological: Ramucirumab DP; Biological: IMC-18F1
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified March 2012
ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy

Condition: Hepatocellular Carcinoma
Interventions: Drug: ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol); Drug: Placebo
Sponsors: Polaris Group; Polaris Group
Recruiting - verified March 2012
Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Conditions: Indolent Non-Hodgkin Lymphoma; Follicular Lymphoma; Small Lymphocytic Lymphoma; Lymphoplasmacytoid Lymphoma; Marginal Zone Lymphoma
Intervention: Drug: CAL-101
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012
Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma

Condition: Sarcoma
Interventions: Drug: everolimus; Drug: imatinib mesylate; Genetic: protein expression analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified August 2011
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)

Condition: Glioblastoma Multiforme
Interventions: Biological: ICT-107; Biological: Placebo DC
Sponsors: ImmunoCellular Therapeutics, Ltd.; ImmunoCellular Therapeutics, Ltd.
Recruiting - verified May 2012
Therapy for Erectile Dysfunction Adaptation of ACT for Compliance With an Erectile Rehabilitation Program

Condition: Prostate Cancer
Interventions: Behavioral: Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls; Behavioral: Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH); Center for Marital and Sexual Health of South Florida
Recruiting - verified November 2011
Study of REOLYSIN® in Combination With FOLFIRI in Patients With Oxaliplatin Refractory/Intolerant KRAS Mutant Colorectal Cancer

Condition: Oxaliplatin Refractory/Intolerant KRAS Mutant Colorectal Cancer
Interventions: Biological: REOLYSIN; Drug: Irinotecan; Drug: Leucovorin; Drug: Fluorouracil (5-FU)
Sponsors: Oncolytics Biotech; Oncolytics Biotech; Montefiore Medical Center
Recruiting - verified December 2011
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: imetelstat sodium; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction

Conditions: Neoplasms; Lymphomas
Intervention: Drug: Belinostat
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: systemic chemotherapy; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

Condition: Breast Cancer
Intervention: Drug: pertuzumab in combination with trastuzumab and paclitaxel
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech; University of Pennsylvania
Recruiting - verified April 2012
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study

Condition: Solid Organ Tumors
Intervention:
Sponsors: Precision Therapeutics; Precision Therapeutics
Recruiting - verified January 2012
Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Biological: bavituximab; Drug: Gemcitabine
Sponsors: Peregrine Pharmaceuticals; Peregrine Pharmaceuticals
Recruiting - verified May 2012
Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Intervention: Drug: IMMU-130
Sponsors: Immunomedics, Inc.; Immunomedics, Inc.
Recruiting - verified April 2012
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Eribulin Mesylate
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified March 2012
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Condition: Melanoma (Skin)
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

Conditions: Non-Hodgkin's Lymphoma; Active Solid Malignancy
Intervention: Drug: PET Imaging using 124 IPUH71
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma

Condition: HEAD & NECK Cancer
Intervention: Drug: ribavirin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: GDC-0973
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified February 2012
Brivanib in Treating Patients With Persistent or Recurrent Cervical Cancer

Condition: Cervical Cancer
Interventions: Drug: brivanib alaninate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Conditions: Neoplasm Metastases; Hepatic Insufficiency
Interventions: Drug: Hepatic dysfunction group; Drug: Control group
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; PharmaMar
Recruiting - verified May 2012
Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

Condition: Small Cell Lung Cancer
Intervention: Drug: ADI-PEG 20 (Arginine deiminase pegylated)
Sponsors: Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; Memorial Sloan-Kettering Cancer Center; Duke University; Polaris Group
Recruiting - verified April 2012
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Biological: IMA901 plus GM-CSF; Drug: Cyclophosphamide
Sponsors: immatics Biotechnologies GmbH; immatics Biotechnologies GmbH
Recruiting - verified May 2012
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer

Conditions: Anemia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small-Cell Lung; Bladder Cancer; Cancer of Head and Neck; Uterine Cervical Cancer
Interventions: Drug: ACE-011 - 15 mg; Drug: ACE-011 - 30 mg; Drug: ACE-011 - 45 mg
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified February 2012
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Carboplatin/Paclitaxel/MEDI-575; Drug: Carboplatin/Paclitaxel; Drug: Carboplatin/Paclitaxel/MEDI-575
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012
Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab (Bevacizumab) For Treatment Of Relapsed/Refractory Glioblastoma Multiforme And Anaplastic Astrocytoma.

Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma
Interventions: Drug: Bevacizumab; Drug: Bevacizumab
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012
Narrow Band Imaging (NBI): A Novel Imaging Modality in Laparoscopic and Robotic Surgery

Conditions: Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Intervention: Other: Narrow Band Imaging (NBI)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012
MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Intervention: Drug: Akt inhibitor MK2206
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Condition: Pain
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2011
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)

Condition: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib; Drug: VT-122 (propranolol plus etodolac); Drug: Placebo
Sponsors: Vicus Therapeutics; Vicus Therapeutics
Recruiting - verified May 2012
Lapatinib in Stage IV Melanoma With ERBB4 Mutations

Condition: Malignant Melanoma
Intervention: Drug: Lapatinib
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011
PET Imaging of Patients With Melanoma Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study

Condition: Newly Diagnosed or Recurrent Metastatic Melanoma Patients
Intervention: Drug: PET scan with 124I-cRGDY-PEG-dots
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy

Condition: Malignant Pleural Mesothelioma
Interventions: Biological: WT-1-vaccine Montanide + GM-CSF; Biological: Montanide adjuvant + GM-CSF
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Department of Defense
Recruiting - verified March 2012
Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events

Condition: High Risk for Postoperative Cardiovascular Events
Intervention: Other: endothelial function testing
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

Condition: Bladder Cancer
Intervention: Drug: Everolimus and Intravesical Gemcitabine
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified March 2012
EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation

Condition: Brain Cancer
Interventions: Drug: erlotinib; Drug: erlotinib
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech; OSI Pharmaceuticals
Recruiting - verified October 2011
Image Guided Therapy in the Treatment of Gliomas

Condition: Glioma
Interventions: Procedure: Diffusion-weighted magnetic resonance imaging; Procedure: Perfusion-weighted magnetic resonance imaging; Procedure: Functional magnetic resonance imaging; Procedure: Magnetic resonance spectroscopic imaging; Procedure: Therapeutic conventional surgery; Procedure: Quality-of-life assessment; Radiation: Radiation therapy treatment planning/simulation; Radiation: Intensity-modulated radiation therapy; Other: Questionnaire administration
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified February 2012
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

Condition: Urothelial Carcinoma
Intervention: Drug: Gemcitabine and Cisplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM1)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012
Veliparib and Carboplatin in Treating Women With HER2-Negative Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: carboplatin; Drug: veliparib; Other: 3'-deoxy-3'-[18F]fluorothymidine; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified April 2012
Aldesleukin With or Without Aflibercept in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Condition: Melanoma (Skin)
Interventions: Biological: aflibercept; Biological: aldesleukin
Sponsors: National Cancer Institute (NCI); Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified July 2011
Phase 1 and 2 Study of PX-866 and Cetuximab

Conditions: Incurable Metastatic Colorectal Carcinoma; Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: PX-866 and cetuximab; Drug: Cetuximab; Drug: PX-866 and cetuximab; Drug: Cetuximab
Sponsors: Oncothyreon Inc.; Oncothyreon Inc.
Recruiting - verified April 2012
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Condition: Uveal Melanoma
Intervention: Drug: RAD001 (Everolimus) and Pasireotide (SOM230) LAR
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified April 2012
Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

Conditions: Anal Cancer; Breast Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Lung Cancer; Nonneoplastic Condition; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: vorinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: carboplatin; Drug: carboplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Recruiting - verified November 2011
Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast

Condition: Breast Cancer
Intervention: Device: Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: BKM120; Drug: BEZ235; Drug: Letrozole; Drug: BKM120
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center
Recruiting - verified July 2011
Survivin Vaccine Therapy for Patients With Malignant Gliomas

Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Tumor
Interventions: Drug: Montanide ISA-51/survivin peptide vaccine; Biological: sargramostim; Other: flow cytometry; Other: laboratory biomarker analysis; Other: immunoenzyme technique
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Not yet recruiting - verified January 2012
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumor

Condition: Advanced Solid Tumors
Interventions: Drug: MEDI3617; Drug: MEDI3617 - Dose Expansion (CRC); Drug: MEDI3617 - Dose Expansion (NSCLC); Drug: MEDI3617 Single-Agent Optional Dose Expansion; Drug: MEDI3617 + Bev Q3W Dose Escalation; Drug: MEDI3617 + Bev Q2W Dose Escalation; Drug: MEDI3617 + Bev Optional Dose Expansion; Drug: MEDI3617 + Weekly Pax Dose Escalation; Drug: MEDI3617 + Pax & Carbo Q3W Dos Esc; Drug: MEDI3617 + Gem & Carbo Q3W Dos Esc
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012
Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

Conditions: Fallopian Tubes; Ovarian Cancer; Peritoneal Cancer
Intervention: Biological: Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012
Pulsed Electromagnetic Fields (PEMF) and Post-Axillary Surgery Morbidity

Condition: Shoulder Symptoms After Lymph Node Dissection
Interventions: Device: PEMF Device; Device: Sham PEMF Device
Sponsors: Columbia University; Columbia University; Ivivi Health Sciences, LLC
Recruiting - verified December 2011
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma, Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Bortezomib, proteasome inhibitor; intravenous; Drug: Dexamethasone, steroid; oral; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified June 2011
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: palliative surgery; Procedure: therapeutic conventional surgery; Radiation: palliative radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention; Other: counseling intervention; Other: educational intervention; Procedure: therapeutic dietary intervention
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Colonoscopy Versus Fecal Immunochemical Testing in Reducing Mortality From Colorectal Cancer (CONFIRM)

Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified April 2012
GDC-0449 in Treating Younger Patients With Recurrent or Refractory Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: vismodegib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer

Conditions: Stomach Cancer; Esophageal Cancer
Interventions: Biological: Ramucirumab; Drug: Placebo; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
The Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients

Condition: Cancer Patients Who Are Undergoing Chemotherapy Treatments and Are Experiencing Cognitive Difficulties.
Interventions: Drug: Ibuprofen; Behavioral: Home-Based Exercise (EXCAP); Drug: Placebo (sugar pill)
Sponsors: University of Rochester; University of Rochester; National Institutes of Health (NIH)
Recruiting - verified August 2011
A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma

Conditions: Advanced Solid Tumor; Lymphomas
Intervention: Drug: LEE011
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

Condition: Breast Cancer
Interventions: Biological: Ramucirumab DP; Biological: IMC-18F1; Drug: Capecitabine
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012
Multiple Ascending Dose of BMS-911543

Condition: Cancer
Intervention: Drug: BMS-911543
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2011
PH III Relapse or Refractory MM - Open Label With or Without Elotuzumab

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Condition: Castrate-Resistant Prostate Cancer
Interventions: Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: Prednisone; Drug: Docetaxel
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals
Recruiting - verified April 2012
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: tasquinimod
Sponsors: Active Biotech AB; Active Biotech AB
Recruiting - verified April 2012
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Super-Selective Intraarterial Cerebral Infusion of Cetuximab for the Treatment of Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma

Conditions: Glioblastoma Multiforme (GBM); ANAPLASTIC ASTROCYTOMA (AOA)
Intervention: Drug: Superselective Intraarterial Cerebral Infusion of Cetuximab
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012
Fertility Preservation in Female Cancer Patients

Condition: Fertility
Intervention: Procedure: oocyte vitrification
Sponsors: North Shore Long Island Jewish Health System; North Shore Long Island Jewish Health System
Recruiting - verified July 2011
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Conditions: Islet Cell Tumor; Pancreatic Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1

Condition: NY-ESO-1 Positive Solid Tumors or Melanoma
Intervention: Biological: IMF-001
Sponsors: ImmunoFrontier, Inc.; ImmunoFrontier, Inc.
Recruiting - verified January 2012
A Study of LY2157299 in Patients With Hepatocellular Carcinoma

Conditions: Carcinoma; Hepatocellular
Intervention: Drug: LY2157299
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma

Condition: Metastatic Pancreatic Adenocarcinoma
Intervention: Drug: CO-1.01
Sponsors: Clovis Oncology, Inc.; Clovis Oncology, Inc.
Recruiting - verified March 2012
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Conditions: Cognitive/Functional Effects; Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: cognitive assessment; Procedure: quality-of-life assessment; Radiation: intensity-modulated radiation therapy; Radiation: whole-brain radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy

Conditions: Clinical Stage T2b or Less of Prostate Cancer; Prostate Brachytherapy; Transrectal Prostate Ultrasound Treatment Planning
Interventions: Other: An ultrasound-based technique to identify prostate cancer; Other: pre-implant transrectal ultrasound images and planning; Other: ultrasound-based cancer-specific images
Sponsors: Beth Israel Medical Center; Beth Israel Medical Center; Riverside Research Instutute,New York, NY
Recruiting - verified January 2012
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Advanced Prostate Cancer

Condition: Prostate Neoplasms
Intervention: Drug: ASG-5ME
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Seattle Genetics, Inc.
Recruiting - verified March 2012
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

Condition: Cancer
Interventions: Drug: GSK2118436; Drug: GSK1120212; Drug: Other approved anti-cancer agent
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Multi-Institutional Registry for Prostate Cancer Radiosurgery

Conditions: Prostate Cancer Treated by Radiosurgery Early Risk; Prostate Cancer Treated by Radiosurgery Intermediate Risk
Intervention:
Sponsors: Florida Robotic Radiosurgery Association; Florida Robotic Radiosurgery Association
Recruiting - verified April 2012
BIBF 1120 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Condition: Endometrial Cancer
Intervention: Drug: multitargeted tyrosine kinase inhibitor BIBF 1120
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Vitamin D and Breast Cancer Biomarkers in Female Patients

Condition: Breast Cancer
Interventions: Dietary Supplement: vitamin D; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer

Condition: Bladder Cancer
Interventions: Procedure: therapeutic conventional surgery; Procedure: therapeutic lymphadenectomy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab

Conditions: Fallopian Tubes Cancer; Ovarian Cancer; Peritoneal Cancer
Intervention: Biological: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified February 2012
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

Conditions: Melanoma; Ovarian Cancer; Sarcoma; BONE; CNS-SPINAL CD/MEMBR,NOS; LYMPH NODES; SOFT TISSUE
Interventions: Radiation: IGIMRT using a single dose of 24 Gy; Radiation: IGIMRT 27 Gy in 3 fractions
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Pisa
Recruiting - verified March 2012
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Conditions: Renal Cell Carcinoma; Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Tesetaxel as First-line Therapy for Metastatic Breast Cancer

Condition: Breast Neoplasm
Intervention: Drug: Tesetaxel
Sponsors: Genta Incorporated; Genta Incorporated
Recruiting - verified November 2011
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma

Condition: Pancreatic Cancer
Intervention:
Sponsors: Columbia University; Columbia University; Cold Spring Harbor Laboratory
Recruiting - verified February 2012
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: irinotecan hydrochloride; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Vinorelbine Ditartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: temsirolimus; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Conditions: Non Small Cell Lung Cancer; NSCLC
Interventions: Drug: OSI-906; Drug: Erlotinib; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2012
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse

Conditions: Patients With Multiple Myeloma Experiencing a; First or Second Relapse
Intervention: Drug: IPH2101 combined to lenalidomide
Sponsors: Innate Pharma; Innate Pharma
Recruiting - verified October 2011
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified April 2012
Tesetaxel for Previously Treated Patients With Bladder Cancer

Condition: Carcinoma, Transitional Cell
Intervention: Drug: Tesetaxel
Sponsors: Genta Incorporated; Genta Incorporated
Recruiting - verified November 2011
A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung

Condition: Adenocarcinoma of the Lung
Interventions: Biological: farletuzumab; Other: Placebo; Drug: Platinum Containing Doublet
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2012
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Conditions: Melanoma; NY-ESO-1-positive; Progressive Metastatic Cutaneous Melanoma; Unresectable
Intervention: Biological: GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified February 2012
Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers

Conditions: Gastric Cancer; Lung Cancer
Interventions: Procedure: respiration correlated CT scan; Procedure: respiration correlated CT scan
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of North Carolina, Chapel Hill; Varian Medical Systems
Recruiting - verified March 2012
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Conditions: Transitional Cell Carcinoma; Bladder Carcinoma; Urothelial Carcinoma
Interventions: Drug: Everolimus; Drug: Everolimus; Drug: Paclitaxel
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Novartis Pharmaceuticals
Recruiting - verified March 2012
Fluorescent Evaluation of Colorectal Anastamoses

Conditions: Rectal Neoplasms; Colon Neoplasms; Diverticulitis
Intervention: Device: Indocyanine Green
Sponsors: Maimonides Medical Center; Maimonides Medical Center
Recruiting - verified April 2012
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

Condition: NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: Drug: U3-1287; Drug: Erlotinib
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified May 2012
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Dovitinib; Drug: Sorafenib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

Conditions: Anal Cancer; Nonneoplastic Condition; Penile Cancer; Precancerous Condition
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Dexamethasone; Procedure: Autologous Stem Cell Transplant
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Emory University; University of Michigan; Fox Chase Cancer Center; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center; Barbara Ann Karmanos Cancer Institute; Duke University; University of California, San Francisco; University of Chicago; M.D. Anderson Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified July 2011
Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: multiple beams utilizing either intensity-modulated or 3D-conformal techniques
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Study of PX-866 and Docetaxel in Solid Tumors

Conditions: Non Small Cell Lung Cancer (NSCLC); Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Drug: Docetaxel; Drug: PX-866 and Docetaxel
Sponsors: Oncothyreon Inc.; Oncothyreon Inc.
Recruiting - verified March 2012
PD0332991 in Patients With Advanced or Metastatic Liposarcoma

Conditions: Sarcoma; Liposarcoma
Intervention: Drug: PD0332991
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Pfizer
Recruiting - verified March 2012
A Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

Conditions: AML; ALL; CML in Blast Crisis; High-Risk MDS; Multiple Myeloma
Intervention: Drug: TG02 citrate
Sponsors: Tragara Pharmaceuticals, Inc.; Tragara Pharmaceuticals, Inc.
Recruiting - verified December 2011
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

Conditions: Bladder Neoplasm; Intravesical Drug Administration; Neoplasm Recurrence, Local; Transitional Cell, Carcinoma; Carcinoma in Situ; Mycobacterium
Intervention: Biological: EN3348
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals
Recruiting - verified February 2012
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: trastuzumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Condition: Hormone Refractory Prostate Cancer
Interventions: Drug: Docetaxel; Drug: TroVax + Docetaxel
Sponsors: Oxford BioMedica; Oxford BioMedica; MedSource
Recruiting - verified February 2012
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Condition: Cancer
Interventions: Drug: Trametinib (GSK1120212); Drug: Docetaxel; Drug: Erlotinib; Drug: Pemetrexed; Drug: Carboplatin; Drug: nab-Paclitaxel; Drug: Cisplatin
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: AMG 386 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

Condition: Melanoma (Skin)
Interventions: Drug: cisplatin; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Drug: temozolomide; Drug: vinblastine sulfate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2011
Characterization of Rectal Cancer Hypoxia Using pO2 Histography and Immunohistochemistry for Hypoxia-Related Proteins

Condition: Rectal Cancer
Intervention: Procedure: Eppendorf hypoximeter
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

Conditions: Sarcoma; Desmoplastic Small Round Cell Tumor (DSRCT)
Intervention: Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified March 2012
Dose Escalation, Combination Chemotherapy Safety Study of TL32711, in Subjects With Advanced or Metastatic Solid Tumors

Condition: Cancer
Interventions: Drug: TL32711; Drug: TL32711
Sponsors: TetraLogic Pharmaceuticals; TetraLogic Pharmaceuticals
Recruiting - verified November 2011
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)

Conditions: Leukemia; Acute Myeloid Leukemia; Acute Nonlymphocytic Leukemia
Interventions: Drug: vosaroxin and cytarabine; Drug: placebo and cytarabine
Sponsors: Sunesis Pharmaceuticals; Sunesis Pharmaceuticals
Recruiting - verified April 2012
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Condition: Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Interventions: Drug: OSI-906; Drug: erlotinib; Drug: placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified April 2012
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

Conditions: Multiple Myeloma; Relapsed Multiple Myeloma; Refractory Multiple Myeloma
Intervention: Drug: AT7519M, Bortezomib
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals; Multiple Myeloma Research Consortium
Recruiting - verified July 2011
Rehabilitation of Cognitive Changes in Breast Cancer Survivors

Condition: Breast Cancer
Intervention: Behavioral: Cogmed Working Memory Training Program
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; MARTELL FOUNDATION
Recruiting - verified October 2011
Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies

Conditions: Bladder Cancer; Renal Pelvis Cancer; Ureter Cancer
Intervention: Drug: gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified April 2012
Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life

Condition: Squamous Cell Carcinoma of the Oropharynx
Intervention: Behavioral: questionnaire and semi-structured interviews
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012
A Study of IMC-3G3 in Soft Tissue Sarcoma

Condition: Sarcoma, Soft Tissue
Interventions: Biological: IMC-3G3; Drug: doxorubicin; Drug: dexrazoxane
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified April 2012
Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: MetMAb; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified March 2012
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Diffuse Adenocarcinoma of the Stomach; Intestinal Adenocarcinoma of the Stomach; Mixed Adenocarcinoma of the Stomach; Recurrent Esophageal Cancer; Recurrent Gastric Cancer; Squamous Cell Carcinoma of the Esophagus; Stage III Esophageal Cancer; Stage III Gastric Cancer; Stage IV Esophageal Cancer; Stage IV Gastric Cancer
Interventions: Drug: pralatrexate; Drug: oxaliplatin; Other: pharmacogenomic studies; Genetic: RNA analysis; Genetic: polymorphism analysis; Genetic: polymerase chain reaction; Genetic: microarray analysis; Procedure: esophagogastroduodenoscopy; Procedure: biopsy; Other: laboratory biomarker analysis
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Comprehensive Cancer Network
Recruiting - verified January 2012
Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer

Conditions: Biliary Tract Cancer; Gallbladder Cancer
Interventions: Drug: Panitumumab; Drug: oxaliplatin; Drug: gemcitabine
Sponsors: University of Rochester; University of Rochester; Amgen
Recruiting - verified November 2011
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow

Condition: Neuroblastoma
Intervention: Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma

Condition: Neuroblastoma
Intervention: Drug: 3F8 and 13-cis-retinoic acid
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation

Condition: Neuroblastoma
Intervention: Drug: 3F8 monoclonal antibody and 13-cis-Retinoic Acid
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma

Condition: Neuroblastoma
Intervention: Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Conditions: Multiple Myeloma; Diffuse Large B-Cell Lymphoma; Glioblastoma Multiforme; Hepatocellular Carcinoma; Non-Small Cell Lung Cancer; Gastrointestinal Neuroendocrine Tumors of Non-Pancreatic Origin; Hormone Receptor-Positive Breast Cancer
Intervention: Drug: CC-223
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
A Study in Second Line Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2012
Trial Of Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (TEMODAR) For Treatment Of Newly Diagnosed Glioblastoma Multiforme And Anaplastic Astrocytoma

Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma
Intervention: Drug: Super-Selective Intraarterial Intracranial Infusion of Temozolomide
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012
Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in the Treatment of Patients With Castration-Resistant Prostate Cancer Resistant to Docetaxel

Condition: Prostate Cancer
Intervention: Biological: Cancer Macrobead placement in abdominal cavity
Sponsors: The Rogosin Institute; The Rogosin Institute
Recruiting - verified April 2012
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Conditions: Prostate Cancer; Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: vorinostat; Drug: temsirolimus; Other: laboratory biomarker analysis; Procedure: positron emission tomography/computed tomography
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies

Condition: Neoplasms
Intervention: Drug: BAY1000394
Sponsors: Bayer; Bayer
Recruiting - verified May 2012
Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)

Condition: Small Cell Lung Cancer
Intervention:
Sponsors: University of Kansas; University of Kansas; Department of Veterans Affairs; University of Pennsylvania; Coney Island Hospital, Brooklyn, NY; University of Nebraska
Recruiting - verified October 2011
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)

Condition: Prostate Cancer
Intervention: Drug: ARN-509
Sponsors: Aragon Pharmaceuticals, Inc.; Aragon Pharmaceuticals, Inc.
Recruiting - verified March 2012
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

Conditions: Anal Cancer; Neoplasm of Uncertain Malignant Potential; Nonneoplastic Condition; Precancerous Condition
Interventions: Other: clinical observation; Procedure: infrared photocoagulation therapy
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified November 2011
A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Patients Who Received Prior First Line Platinum Based Chemotherapy

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel; Biological: Ramucirumab; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2012
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Conditions: Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer
Interventions: Drug: panobinostat; Drug: everolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Other: liquid chromatography; Other: mass spectrometry; Other: enzyme-linked immunosorbent assay; Other: immunohistochemistry staining method
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Cancer Institute (NCI); Novartis
Recruiting - verified April 2012
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: ruxolitinib phosphate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity

Conditions: Pleural Metastases; Breast Cancer; Colon Cancer; Ovarian Cancer; Uterine Cancer; Renal Cell Cancer; Thymic Cancer
Intervention: Procedure: Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
Sponsors: St. Luke's-Roosevelt Hospital Center; St. Luke's-Roosevelt Hospital Center
Recruiting - verified September 2011
Acupuncture Study for the Prevention of Taxane Induced Myalgias and Neuropathy

Conditions: Taxane Induced Neuropathy; Breast Cancer
Interventions: Other: Electro-acupuncture; Other: Sham acupuncture
Sponsors: Columbia University; Columbia University; Breast Cancer Research Foundation
Recruiting - verified October 2011
Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence

Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

Condition: Soft Tissue Sarcoma
Interventions: Drug: doxorubicin in combination with palifosfamide-tris; Drug: doxorubicin in combination with placebo
Sponsors: ZIOPHARM; ZIOPHARM
Recruiting - verified April 2012
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Condition: Carcinoma, Squamous Cell of the Head and Neck
Interventions: Biological: REOLYSIN; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: Oncolytics Biotech; Oncolytics Biotech
Recruiting - verified March 2012
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: 1121B (ramucirumab); Drug: Pemetrexed; Drug: Carboplatin (AUC 6); Drug: Cisplatin; Drug: Gemcitabine; Drug: Carboplatin (AUC 5)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified December 2011
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®); Drug: placebo; Drug: EC20
Sponsors: Endocyte; Endocyte
Recruiting - verified March 2012
Exercise Program of Breast Cancer Patients Undergoing Chemotherapy With or Without Radiation

Condition: Breast Cancer
Intervention: Other: standardized regimen of exercises, including a warm-up period, ROM arm exercises, and strength training exercises.
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011
MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Kidney Cancer; Leukemia; Liver Cancer; Neuroblastoma; Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

Conditions: Minimal Residual Disease; Leukemia, Lymphoblastic, Acute; Leukemia, Myelogenous, Acute
Interventions: Drug: Clofarabine; Drug: Cytarabine; Drug: Methotrexate; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Genzyme
Recruiting - verified November 2011
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Interpersonal Therapy for Depression in Breast Cancer

Condition: Major Depression
Interventions: Behavioral: Interpersonal Psychotherapy; Behavioral: Problem-Solving Therapy; Behavioral: Brief Supportive Psychotherapy
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute
Recruiting - verified February 2012
Dose Response of Functionally Critical Brain Regions for Brain Radiotherapy

Condition: Brain Tumors
Intervention: Procedure: fMRI Evaluation
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: fowlpox-PSA-TRICOM vaccine; Biological: vaccinia-PSA-TRICOM vaccine; Drug: docetaxel; Drug: prednisone
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2011
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: cixutumumab; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

Condition: Thyroid Cancer
Intervention: Drug: sorafenib with everolimus
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

Conditions: Breast Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: questionnaire administration; Procedure: evaluation of cancer risk factors; Procedure: quality-of-life assessment; Procedure: study of high risk factors
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

Condition: Prostate Cancer
Interventions: Biological: engineered autologous T cells; Drug: cyclophosphamide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Department of Defense
Recruiting - verified March 2012
Temozolomide or MEK Inhibitor AZD6244 (Selumetinib) in Treating Patients With Metastatic Melanoma of the Eye

Condition: Intraocular Melanoma
Interventions: Drug: selumetinib; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx

Conditions: Dysplasia; Carcinoma of the Oral Cavity; Carcinoma of the Oropharynx
Intervention: Drug: HPPH
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Other: cytology specimen collection procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

Condition: Sarcoma
Interventions: Biological: Trivalent ganglioside vaccine; Biological: OPT-821
Sponsors: MabVax Therapeutics, Inc.; MabVax Therapeutics, Inc.
Recruiting - verified March 2012
Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life

Condition: Breast Cancer
Interventions: Behavioral: survey web-based or telephone interview; Behavioral: survey web-based or telephone interview
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; The City College of New York; New York City Health and Hospitals Corporation; Lincoln Medical and Mental Health Center; New York Hospital Queens; Ralph Lauren Center for Cancer Care and Prevention
Recruiting - verified May 2012
Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage

Conditions: Gastric Cancer; Pancreatic Cancer
Intervention: Procedure: Diagnostic peritoneal lavage
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

Conditions: Cachexia; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific; Weight Changes
Interventions: Drug: cyproheptadine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified December 2011
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib

Condition: Hepatocellular Carcinoma
Interventions: Biological: Placebo; Biological: Ramucirumab DP (IMC-1121B)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012
An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Condition: Unresectable Stage III or Stage IV Melanoma
Interventions: Drug: E7080; Drug: E7080
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified January 2012
Neoadjuvant Therapy for Ovarian Cancer

Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Intervention: Drug: Carboplatin, paclitaxel, and bevacizumab
Sponsors: Columbia University; Columbia University; Genentech
Recruiting - verified October 2011
Local Invasion of Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention:
Sponsors: Columbia University; Columbia University
Recruiting - verified February 2012
Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: Multi-Beam Intensity-Modulated Radiation Therapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions

Condition: Multiple Myeloma
Interventions: Drug: busulfan, melphalan and fludarabine; Drug: busulfan, melphalan and fludarabine
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Otsuka America Pharmaceutical
Recruiting - verified January 2012
A Pilot Study of Docosahexaenoic Acid (DHA) in Obese Menopausal Women

Conditions: Breast Cancer; Rectal Cancer; Colon Cancer; Obesity
Intervention: Dietary Supplement: dietary intervention
Sponsors: Rockefeller University; Rockefeller University
Recruiting - verified April 2012
RAD001 Plus Carboplatin in Breast Cancer Patients

Condition: Breast Cancer
Intervention: Drug: RAD001
Sponsors: New York University School of Medicine; New York University School of Medicine; Novartis Pharmaceuticals
Recruiting - verified December 2011
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: E7080; Drug: Everolimus; Drug: E7080 plus Everolimus
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Cell Culture of Glioma Specimens for in Vitro Preclinical Studies

Condition: Brain Tumor
Intervention:
Sponsors: Albany Medical College; Albany Medical College
Recruiting - verified April 2009
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

Condition: Thrombocytopaenia
Interventions: Drug: Eltrombopag olamine; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Confocal Endomicroscopy for Improved Diagnosis of Barrett's Esophagus and Early Esophageal Cancer(CEBE Study)

Condition: Barrett's Esophagus, Esophageal Intraepithelial Neoplasia
Intervention: Procedure: endomicroscopy
Sponsors: Johns Hopkins University; Johns Hopkins University; American Society for Gastrointestinal Endoscopy; Pentax Medical Corporation
Recruiting - verified March 2012
RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: trastuzumab; Drug: vinorelbine; Drug: vinorelbine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

Condition: Kidney Cancer
Interventions: Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: cixutumumab; Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
A Dose Finding and Safety Study of Oral LDE225 in Children

Conditions: Medulloblastoma,; Rhabdomyosarcoma,; Neuroblastoma,; Hepatoblastoma,; High Grade Glioma,; Astrocytoma
Intervention: Drug: LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab

Conditions: Metastatic Breast Cancer; Trastuzumab; BKM120; HER2+
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Childhood Cancer Survivor Study

Condition: Cancer
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI); Fred Hutchinson Cancer Research Center; Nationwide Children's Hospital; M.D. Anderson Cancer Center; University of Southern California; Children's Hospital Medical Center, Cincinnati
Recruiting - verified April 2012
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Drug: temozolomide; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Tracking Renal Tumors After Cryoablation Evaluation

Condition: Kidney Neoplasms
Intervention: Procedure: Cryoablation
Sponsors: Galil Medical; Galil Medical
Recruiting - verified October 2011
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients

Conditions: Lymphoma, Non-Hodgkin; Hodgkin Disease; Multiple Myeloma
Interventions: Drug: TXA127; Drug: Placebo
Sponsors: US Biotest, Inc.; US Biotest, Inc.; Tarix Pharmaceuticals
Recruiting - verified April 2012
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies

Conditions: Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Myelodysplastic Syndrome; Multiple Myeloma
Interventions: Device: CliniMACS Fractionation system; Device: CliniMACS Fractionation system; Device: CliniMACS Fractionation system
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: pertuzumab; Drug: pertuzumab-placebo; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified March 2012
A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer

Conditions: Renal Cell Carcinoma; Pharmacokinetics of AGS-16M8F
Intervention: Drug: AGS-16M8F
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Agensys, Inc.
Recruiting - verified March 2012
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Temsirolimus plus Neratinib
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Comprehensive Cancer Network; Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified May 2012
International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients

Conditions: Breast Cancer; Lymphoma
Intervention: Behavioral: questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: pemetrexed disodium
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma

Condition: Neuroblastoma
Intervention: Drug: Bevacizumab, Irinotecan and Temozolomide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified April 2012
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+

Condition: Cervical Intraepithelial Neoplasia
Interventions: Biological: ADXS11-001 (Lm-LLO-E7); Drug: Placebo Control
Sponsors: Advaxis, Inc.; Advaxis, Inc.
Recruiting - verified January 2012
Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery

Conditions: Recurrent Bladder Cancer; Stage 0 Bladder Cancer; Stage I Bladder Cancer; Stage II Bladder Cancer; Transitional Cell Carcinoma of the Bladder
Interventions: Dietary Supplement: broccoli sprout extract; Other: laboratory biomarker analysis
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
A Study of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Conditions: Bone Metastases; Castration-Resistant Prostate Cancer
Interventions: Drug: Alpharadin® (Radium-223 chloride) + docetaxel; Drug: Docetaxel
Sponsors: Algeta ASA; Algeta ASA; Bayer
Recruiting - verified October 2011
Study of E7080 in Subjects With Advanced Endometrial Cancer and Disease Progression

Condition: Endometrial Cancer
Intervention: Drug: E7080
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors

Conditions: Advanced Solid Tumors; Recurrent or Refractory Medulloblastoma; Locally Advanced or Metastatic Basal Cell Carcinoma
Intervention: Drug: LEQ506
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: lenalidomide, bortezomib and dexamethasone; Drug: Lenalidomide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified March 2012
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: letrozole; Drug: panobinostat; Genetic: RNA analysis; Genetic: microarray analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy

Condition: Bladder Cancer
Intervention: Other: external radiation therapy with gemcitabine
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Family and Personal History of Malignancy in Intraductal Papillary Mucinous Neoplasm (IPMN)

Conditions: Pancreatic Cancer; Neoplasm
Intervention:
Sponsors: Columbia University; Columbia University
Recruiting - verified February 2012
Stool Testing for Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention:
Sponsors: Columbia University; Columbia University; Mayo Clinic
Recruiting - verified February 2012
Safety Study of Live Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy

Condition: Solid Tumor Malignancies
Intervention: Biological: Clostridium novyi-NT spores
Sponsors: BioMed Valley Discoveries, Inc; BioMed Valley Discoveries, Inc
Recruiting - verified November 2011
Use of PET Imaging to Distinguish Malignant From Benign IPMN

Conditions: Neoplasm; Pancreatic Cancer
Intervention:
Sponsors: Columbia University; Columbia University; National Center for Research Resources (NCRR)
Recruiting - verified February 2012
Pancreatic Cancer Registry for High Risk Individuals

Condition: Pancreatic Cancer
Intervention:
Sponsors: Columbia University; Columbia University
Recruiting - verified January 2012
Pancreatic Cancer Genetics

Condition: Pancreatic Cancer
Intervention:
Sponsors: Columbia University; Columbia University
Recruiting - verified January 2012
Validation of a Mouse Model of Pancreatic Carcinogenesis

Condition: Pancreatic Cancer
Intervention:
Sponsors: Columbia University; Columbia University
Recruiting - verified February 2012
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma

Condition: Brain Cancer
Intervention: Drug: Temozolomide, bevacizumab, lithium, radiation
Sponsors: New York University School of Medicine; New York University School of Medicine; Genentech; Ohio State University; Atlantic Health System
Recruiting - verified February 2012
Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery

Condition: Cervical Cancer
Interventions: Drug: cisplatin; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: metformin hydrochloride; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: Indibulin
Sponsors: ZIOPHARM; ZIOPHARM; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy

Conditions: Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity
Interventions: Drug: calcium gluconate; Drug: magnesium sulfate; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum

Condition: Peritoneal Cancer
Intervention: Biological: 131 I-8H9/ 124 I-8H9
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Siliphos in Advanced Hepatocellular Carcinoma

Condition: Advanced Hepatocellular Carcinoma
Intervention: Drug: Silybin
Sponsors: Columbia University; Columbia University; Lotte and John Hecht Memorial Foundation
Recruiting - verified October 2011
High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer
Interventions: Dietary Supplement: cholecalciferol; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Elitek (Rasburicase) Immuno-Monitoring Study

Condition: Tumor Lysis Syndrome
Intervention:
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified February 2012
Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection

Conditions: Pancreatic Cancer; Intraductal Papillary Mucinous Neoplasm
Intervention: Drug: Secretin
Sponsors: Columbia University; Columbia University
Recruiting - verified February 2012
Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency

Condition: Pancreatic Cancer
Intervention: Drug: Synthetic Human Secretin
Sponsors: Columbia University; Columbia University
Not yet recruiting - verified July 2011
Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery

Condition: Pancreatic Cancer
Intervention: Drug: Synthetic Human Secretin
Sponsors: Columbia University; Columbia University
Not yet recruiting - verified January 2012
Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

Condition: Advanced Solid Tumors
Interventions: Dietary Supplement: calcitriol; Drug: cisplatin; Drug: gemcitabine hydrochloride; Other: pharmacological study
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma
Intervention: Drug: Irinotecan and Bevacizumab
Sponsors: New York University School of Medicine; New York University School of Medicine; Genentech
Recruiting - verified March 2012
Community-based Approaches to Treating Hypertension and Colon Cancer Prevention

Conditions: Hypertension; Colon Cancer
Interventions: Behavioral: MINT; Behavioral: Patient Navigation
Sponsors: New York University School of Medicine; New York University School of Medicine; Cornell University; Wayne State University
Recruiting - verified July 2011
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Condition: Head and Neck Neoplasms
Interventions: Drug: Pemetrexed; Drug: Cetuximab; Drug: Carboplatin; Drug: Cisplatin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified October 2011
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Conditions: Chronic Lymphocytic Leukemia; Lymphoma, Non-Hodgkin; Acute Myeloid Leukemia; Multiple Myeloma
Intervention: Drug: CAL-101
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified January 2012
Female Cancer Patients' Preference For Sexual Health Interventions

Conditions: Breast Cancer; Gynecologic Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011
Paclitaxel, Cisplatin, and Cetuximab Followed By Cetuximab and Intensity-Modulated Radiation Therapy in Treating Patients With HPV-Associated Stage III or Stage IV Cancer of the Oropharynx That Can Be Removed By Surgery

Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: BIBW 2992 plus cetuximab
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

Condition: Malignant Pleural Mesothelioma
Interventions: Drug: NGR-hTNF plus Best Investigator Choice (BIC); Drug: Placebo plus Best Investigator Choice (BIC)
Sponsors: MolMed S.p.A.; MolMed S.p.A.
Recruiting - verified December 2011
Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery

Condition: Breast Cancer
Interventions: Other: circulating tumor cell analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal accelerated partial breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
A Study in Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cetuximab; Drug: Cisplatin; Drug: Carboplatin; Drug: 5-fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Pemetrexed Disodium or Observation in Treating Patients With Malignant Pleural Mesothelioma Without Progressive Disease After First-Line Chemotherapy

Condition: Malignant Mesothelioma
Interventions: Drug: pemetrexed disodium; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified January 2012
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Biological: ramucirumab; Drug: irinotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Intraarterial Cerebral Infusion of Avastin for Vestibular Schwannoma (Acoustic Neuroma)

Condition: Vestibular Schwannoma
Intervention: Drug: Bevacizumab (Avastin)
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified September 2011
Subtotal Resection of Large Acoustic Neuromas With Possible Stereotactic Radiation Therapy

Condition: Neuroma, Acoustic
Interventions: Procedure: Microsurgery; Procedure: Stereotactic radiation therapy
Sponsors: Stanford University; Stanford University; University of Cincinnati; Baylor College of Medicine; Weill Medical College of Cornell University; University of Iowa; University of Texas; George Washington University
Recruiting - verified March 2012
Connect® MM- The Multiple Myeloma Disease Registry

Condition: Multiple Myeloma
Intervention:
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2011
Randomized Trial Comparing Robotic and Open Radical Cystectomy

Condition: Bladder Cancer
Interventions: Procedure: open radical cystectomy; Procedure: robotic-assisted radical cystectomy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Condition: Chronic Lymphocytic Leukemia
Intervention:
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2011
Immunotherapy Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified May 2012
Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)

Conditions: Pancreatic Cancer Stage II; Pancreatic Cancer Stage III
Interventions: Drug: Neoadjuvant gemcitabine, capecitabine, and docetaxel; Drug: Gemcitabine, capecitabine, docetaxel followed by radiotherapy
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011
Early Prediction of Pathologic Complete Response (pathCR) With Fluoro-L-Thymidine (FLT) Positron Emission Tomography (PET)

Condition: Esophageal Cancer
Intervention: Drug: Fluoro-L-Thymidine
Sponsors: Columbia University; Columbia University; National Cancer Institute (NCI)
Recruiting - verified October 2011
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2012
A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Condition: Advanced Solid Tumors
Interventions: Drug: veliparib (ABT-888); Drug: carboplatin; Drug: gemcitabine
Sponsors: Abbott; Abbott
Recruiting - verified March 2012
Dalteparin in Combination With Sunitinib in Patients With Metastatic Kidney Cancer

Condition: Renal Cell Carcinoma
Intervention: Drug: Sunitinib and Dalteparin mono and combination therapy
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; Pfizer
Recruiting - verified March 2012
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012
Randomized Trial of Restrictive Versus Liberal Perioperative Fluid Management for Patients Undergoing Pancreatic Resection

Condition: Pancreatic Cancer
Interventions: Other: restrictive perioperative fluid management; Other: Liberal perioperative fluid management
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer

Conditions: Pancreatic Cancer; Colorectal Cancer
Intervention: Biological: Cancer macrobead placement in abdominal cavity
Sponsors: The Rogosin Institute; The Rogosin Institute
Recruiting - verified April 2012
Lenalidomide in Treating Patients With AIDS-Related Kaposi Sarcoma

Conditions: Nonneoplastic Condition; Sarcoma
Interventions: Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified December 2011
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: perifosine; Drug: temsirolimus; Genetic: fluorescence in situ hybridization; Genetic: western blotting; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2011
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors

Condition: Pediatric Solid Tumors
Intervention: Drug: perifosine + temsirolimus
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Wisconsin, Madison; Duke University; NATL COMP CA NETWORK; Pfizer; Keryx / AOI Pharmaceuticals, Inc.
Recruiting - verified November 2011
Conservative Surgery for Women With Cervical Cancer

Condition: Cervical Cancer
Intervention: Procedure: Conservative Surgery
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Cone Beam Computed Tomography for Breast Imaging

Condition: Breast Cancer
Interventions: Device: Computed Tomography; Device: Computed Tomography
Sponsors: Koning Corporation; Koning Corporation; Elizabeth Wende Breast Care; National Cancer Institute (NCI)
Recruiting - verified January 2012
Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.

Conditions: Liver Neoplasms; Adenoma; Carcinoma; Liver Abscess
Intervention: Drug: Gadoxetic Acid Disodium (Primovist/Eovist, BAY86-4873)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: celecoxib; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection

Conditions: Multiple Myeloma; Non-Hodgkins Lymphoma
Intervention: Drug: Plerixafor
Sponsors: Shi, Patricia, M.D.; Shi, Patricia, M.D.; Genzyme
Recruiting - verified September 2011
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Conditions: Leukemia; Acute Lymphoblastic Leukemia
Intervention: Biological: gene-modified T cells targeted to B-ALL tumor cells
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2011
Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Carcinoma
Interventions: Drug: Pazopanib; Drug: Doxil
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; GlaxoSmithKline
Recruiting - verified November 2011
Interleukin 2, Aldesleukin and Entinostat for Kidney Cancer

Condition: Renal Cell Carcinoma
Intervention: Drug: Aldesleukin
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

Condition: Carcinoma
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: BNC105P; Drug: Everolimus; Drug: BNC105P
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bionomics Limited
Recruiting - verified March 2012
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

Condition: Recurrent or Refractory Pediatric Ependymoma
Interventions: Drug: erlotinib; Drug: etoposide
Sponsors: OSI Pharmaceuticals; OSI Pharmaceuticals; Astellas Pharma Global Development, Inc.
Recruiting - verified February 2012
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Condition: Melanoma
Intervention: Drug: nilotinib (AMN107)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Biological: anti-thymocyte globulin; Biological: rituximab; Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: methotrexate; Drug: sirolimus; Drug: tacrolimus; Other: laboratory biomarker analysis; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma

Conditions: Thymoma; Clinical Masaoka Stage II-IVA
Intervention: Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb
Recruiting - verified January 2012
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Condition: Malignant Melanoma
Interventions: Drug: BMS-936558 (MDX1106-04); Drug: Ipilimumab (BMS-734016); Drug: BMS-936558 (MDX1106-04); Drug: BMS-936558 (MDX1106-04); Drug: BMS-936558 (MDX1106-04); Drug: BMS-936558 (MDX1106-04); Drug: BMS-936558 (MDX1106-04); Drug: Ipilimumab (BMS-734016)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Medarex; Ono Pharma
Recruiting - verified April 2012
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Conditions: Pancreatic Cancer; Ductal Adrenocarcinoma; Exocrine Pancreatic Cancer
Intervention: Drug: PCI-27483
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified January 2012
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: Seneca Valley virus-001; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Conditions: Squamous Cell Cancer; Head and Neck Cancer
Intervention: Drug: Temsirolimus + Weekly Paclitaxel + Carboplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; NATL COMP CA NETWORK; Pfizer
Recruiting - verified January 2012
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Condition: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2011
Study of Lung Chemotherapy in the Treatment of Advanced Lung Cancer and Metastatic Sarcoma

Conditions: Lung Cancer; Sarcoma
Intervention: Drug: Cisplatin
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas

Condition: Brain Cancer
Intervention: Other: cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Children's Healthcare of Atlanta; Dana-Farber Cancer Institute; M.D. Anderson Cancer Center; Phoenix Children's Hospital; Alberta Children's Hospital; University of Colorado, Denver; Seattle Children's Hospital; Johns Hopkins University; Children's Mercy Hospital-Kansas City, MO; MD Anderson Cancer Center Orlando at Arnold Palmer Hospital for Children
Recruiting - verified March 2012
Percutaneous Renal Tumor Cryoablation Followed by Biopsy

Condition: Renal Cancer
Intervention: Procedure: percutaneous cryoablation
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified October 2011
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: rosuvastatin; Other: placebo
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Electronic Brachytherapy for the Treatment of NMSC

Conditions: Basal Cell Carcinoma; Squamous Cell Carcinoma
Intervention: Radiation: electronic brachytherapy
Sponsors: Xoft, Inc.; Xoft, Inc.
Recruiting - verified March 2012
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

Condition: Sarcoma
Interventions: Drug: bortezomib; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified November 2011
Lisinopril or Carvedilol Phosphate in Reducing Side Effects in Women With HER2-Positive Breast Cancer Receiving Trastuzumab

Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: carvedilol phosphate extended-release capsule; Drug: lisinopril; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified February 2012
Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor

Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Stage IV Surgery Versus Best Medical Therapy

Condition: Stage IV Resectable Melanoma
Interventions: Procedure: Surgery; Procedure: Surgery plus 2 adjuvant doses of BCG; Other: best medical therapy
Sponsors: John Wayne Cancer Institute; John Wayne Cancer Institute; Melanoma Research Alliance
Recruiting - verified May 2012
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer

Condition: Breast Cancer
Intervention: Other: ChemoFX Assay
Sponsors: Precision Therapeutics; Precision Therapeutics; Department of Defense
Recruiting - verified December 2011
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Trastuzumab; Drug: Neratinib; Drug: Trastuzumab (post surgery); Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified February 2012
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts

Condition: Cholangiocarcinoma
Intervention: Drug: Gemcitabine, Capecitabine and Bevacizumab
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; Genentech
Recruiting - verified December 2011
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: doxorubicin-eluting beads; Drug: mitomycin C; Drug: sorafenib tosylate; Other: placebo
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Guided Biopsy for Mapping Prostate Cancer

Condition: Prostate Cancer
Intervention: Procedure: Prostatectomy
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Condition: Lymphoma, Large-Cell, Diffuse
Interventions: Drug: OFATUMUMAB + DHAP; Drug: RITUXIMAB + DHAP
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Adjuvant Valproate for High Grade Sarcomas

Condition: High Grade Sarcoma
Intervention: Drug: Valproic Acid
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Drug: topotecan and erlotinib
Sponsors: New York University School of Medicine; New York University School of Medicine; OSI Pharmaceuticals
Recruiting - verified February 2012
Pemetrexed and Carboplatin in Recurrent Platinum Sensitive Ovarian Cancer

Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: Carboplatin; Drug: Pemetrexed
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified July 2011
Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection

Condition: Melanoma
Intervention: Behavioral: screening questionnaire
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of British Columbia; San Diego State University; Stony Brook University
Recruiting - verified January 2012
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors

Condition: Triple Negative Breast Cancer
Intervention: Drug: Temsirolimus, cisplatin, erlotinib
Sponsors: Columbia University; Columbia University; Wyeth is now a wholly owned subsidiary of Pfizer; Genentech
Recruiting - verified October 2011
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: AEterna Zentaris; AEterna Zentaris; Dana-Farber Cancer Institute
Recruiting - verified February 2012
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: BT062
Sponsors: Biotest Pharmaceuticals Corporation; Biotest Pharmaceuticals Corporation; Biotest
Recruiting - verified December 2011
Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients

Condition: Hepatocellular Cancer
Intervention: Drug: Sorafenib - dose escalation
Sponsors: Columbia University; Columbia University; Bayer; Onyx Pharmaceuticals
Recruiting - verified October 2011
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Pemetrexed, Cisplatin, Bevacizumab
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

Condition: Pancreatic Cancer
Interventions: Drug: Pasireotide (SOM230); Other: placebo
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified December 2011
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

Condition: Carcinoma
Interventions: Biological: REOLYSIN; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Oncolytics Biotech; Oncolytics Biotech; University of Texas
Recruiting - verified December 2011
Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor

Condition: Breast Cancer
Intervention: Radiation: Radiation therapy
Sponsors: New York University School of Medicine; New York University School of Medicine; department of radiation oncology
Recruiting - verified November 2011
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

Condition: Cancer
Intervention: Drug: TL32711
Sponsors: TetraLogic Pharmaceuticals; TetraLogic Pharmaceuticals
Recruiting - verified November 2011
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma

Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Biological: REOLYSIN; Drug: Gemcitabine
Sponsors: Oncolytics Biotech; Oncolytics Biotech; University of Texas
Recruiting - verified May 2011
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma

Condition: Mesothelioma
Intervention: Drug: Velcade (bortezomib) plus Eloxatin (oxaliplatin)
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Drug: veliparib
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
IMGN901 in Combination With Lenalidomide and Dexamethasone

Condition: Multiple Myeloma
Intervention: Drug: IMGN901
Sponsors: ImmunoGen, Inc.; ImmunoGen, Inc.
Recruiting - verified October 2011
Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen

Conditions: Atrophic Vaginitis; Breast Cancer
Intervention: Drug: Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Geriatric Group Psychoeducational Intervention for Elderly Patients With Cancer

Conditions: Breast Cancer; Prostate Cancer; Lung Cancer; Lymphoma Cancer; Gynecological Cancers
Interventions: Behavioral: group intervention and questionnaires; Behavioral: individual phone intervention and questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: mitomycin C
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Image-Guided Stereotactic Biopsy of High Grade Gliomas

Conditions: Brain Cancer; Glioma
Intervention: Procedure: 18F-FLT PET Scan
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

Conditions: Cancer; Advanced Solid Malignancies
Intervention: Drug: AZD4547
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cediranib maleate; Drug: cilengitide; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis; Procedure: magnetic resonance imaging
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10)

Condition: Lung Cancer
Interventions: Biological: panitumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

Condition: Breast Cancer
Interventions: Dietary Supplement: Coenzyme Q10; Dietary Supplement: Coenzyme Q10 Placebo
Sponsors: Columbia University; Columbia University; National Institutes of Health (NIH)
Recruiting - verified October 2011
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients

Condition: Bladder Cancer
Interventions: Drug: Mitomycin C (MMC); Biological: Bacillus Calmette-Guerin (BCG)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; New York Presbyterian Hospital; Weill Medical College of Cornell University
Recruiting - verified January 2012
A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: GDC-0941; Drug: paclitaxel; Drug: pemetrexed; Drug: cisplatin
Sponsors: Genentech; Genentech
Recruiting - verified November 2011
DNA Chip Based Prognosis of Lung Cancer

Condition: Carcinoma, Non-Small-Cell Lung
Intervention:
Sponsors: Medical Prognosis Institute A/S; Medical Prognosis Institute A/S
Recruiting - verified June 2011
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

Condition: Hepatocellular Carcinoma
Interventions: Drug: GC33; Drug: Sorafenib
Sponsors: Chugai Pharmaceutical; Chugai Pharmaceutical; Hoffmann-La Roche
Recruiting - verified April 2012
Cone Beam Computed Tomography for Breast Imaging

Condition: Breast Cancer
Interventions: Radiation: Computed Tomography; Radiation: Computed Tomography; Radiation: Computed Tomography
Sponsors: Koning Corporation; Koning Corporation
Recruiting - verified January 2012
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

Condition: Thyroid Cancer
Intervention: Biological: AZD6244
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genzyme; AstraZeneca
Recruiting - verified January 2012
Characterizing Lone Parenting: A Multi-institutional Pilot Study of the Perceptions of Support and Perceived Stress of Lone Parents of Children With Cancer

Condition: Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified June 2011
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma

Condition: Head and Neck Cancer
Intervention: Other: bevacizumab, cisplatin, cetuximab, radiation therapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified January 2012
Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer

Condition: Parents Who Have Lost a Child to Cancer
Intervention: Behavioral: Questionnaires/Interviews
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI); Dana Farber Cancer Institute/Harvard Medical School; Ohio State University; University of Memphis
Recruiting - verified December 2011
Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)

Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma
Intervention: Drug: Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012
Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral MLN9708 in Adult Patients With Relapsed and Refractory Multiple Myeloma

Condition: Relapsed and Refractory Multiple Myeloma
Intervention: Drug: Oral MLN9708
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer; Psychosocial Effects of Cancer and Its Treatment
Interventions: Other: communication intervention; Other: educational intervention; Other: internet-based intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: management of therapy complications; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer

Conditions: Ovarian Cancer; Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy

Conditions: Penile Cancer; Erectile Dysfunction; Radical Prostatectomy
Interventions: Drug: Placebo QHS and sildenafil and questionnaires; Drug: Sildenafil and questionnaire; Drug: Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Pfizer
Recruiting - verified January 2012
Pioglitazone for Oral Premalignant Lesions

Conditions: Malignant Neoplasm Overlapping Lip Site; Mouth Neoplasms; Malignant Neoplasm of Other and Ill-defined Sites in the Lip, Oral Cavity and Pharynx; Leukoplakia; Other Lesions of Oral Mucosa; Pigmented Oral Mucosal Lesion; Unspecified Lesions of Oral Mucosa; Oral Lichenoid Lesions; Premalignant Lesion; Other and Unspecified Lesions of Oral Mucosa; Granuloma and Granuloma-like Lesions of Oral Mucosa; Diseases of the Oral Soft Tissue, Excluding Lesions Specific for Gingiva and Tongue; Oral Premalignant Lesion; Oral Premalignant Neoplasms; Oral Leukoplakia
Interventions: Drug: Pioglitazone; Drug: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI); University of Minnesota - Clinical and Translational Science Institute; Memorial Sloan-Kettering Cancer Center; University of Wisconsin, Madison; University of Alabama at Birmingham; University of Iowa; University of Maryland; Roswell Park Cancer Institute; Columbia University; Weill Medical College of Cornell University; European Institute of Oncology
Recruiting - verified April 2012
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Condition: Advanced Malignancies
Intervention: Biological: CDX-1401 in combination with Resiquimod and/or Poly-ICLC
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified November 2011
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Conditions: Advanced Non-hematologic Malignancies; Advanced Metastatic Melanoma
Intervention: Drug: TAK-733
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Conditions: Pancreatic Neoplasm; Pituitary Neoplasm; Nelson Syndrome; Ectopic ACTH Syndrome
Intervention: Drug: Pasireotide LAR
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011
An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study

Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2011
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; Indiana University Melvin and Bren Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified March 2012
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors

Condition: Neoplasms
Intervention: Drug: PF-05212384 (also known as PKI-587)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Application of Magnetic Resonance Fat-Free Imaging

Condition: Sarcoma
Intervention: Procedure: Fat-free MRI images utilizing standard magnetization, Questionnaire before the MRI exam
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects

Conditions: Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
Intervention: Procedure: Gynaecological follow-up
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Metformin Pre-Surgical Pilot Study

Condition: Breast Cancer
Intervention: Drug: Metformin
Sponsors: Columbia University; Columbia University; Breast Cancer Research Foundation
Recruiting - verified October 2011
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer

Condition: Solid Cancers
Interventions: Drug: carboplatin; Drug: docetaxel; Drug: trastuzumab
Sponsors: Genentech; Genentech
Recruiting - verified October 2011
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients

Condition: Cancer
Intervention: Drug: PF-04691502
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012
Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy

Conditions: Fatigue; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Behavioral: exercise
Sponsors: University of Rochester; University of Rochester; National Cancer Institute (NCI)
Recruiting - verified March 2012
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis

Conditions: Metastatic Cancer; Pain
Interventions: Radiation: external beam radiation therapy; Radiation: image-guided radiation therapy; Radiation: radiosurgery; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

Conditions: Leukemia-relapsed or Refractory; Cancer
Interventions: Drug: GSK1120212; Drug: GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer

Conditions: Esophageal Cancer; Gastroesophageal Junction Cancer
Interventions: Drug: Sorafenib, administered orally; Procedure: CT/MRI
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bayer
Recruiting - verified April 2012
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device; Drug: Temozolomide
Sponsors: NovoCure Ltd.; NovoCure Ltd.
Recruiting - verified March 2012
Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer

Conditions: Prostate Cancer; Adenocarcinoma
Intervention: Radiation: Hypofractionated, image-guided, intensity-modulated external beam radiation
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Montefiore Medical Center
Recruiting - verified March 2012
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver

Condition: Hepatocellular Carcinoma
Interventions: Biological: IMC-A12 (cixutumumab); Biological: IMC-A12 (cixutumumab); Drug: sorafenib
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified October 2011
Study of Radiation Exposure and Bilateral Breast Cancer

Condition: Breast Cancer
Intervention: Other: questionaire, blood or saliva sample
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Translational Genomics Research Institute, Phoenix, Arizona.; University of Southern California; University of Virginia; Lund University; Ontario Cancer Registry; Northern California Cancer Center; Fred Hutchinson Cancer Research Center; University of Iowa; Danish Cancer Society; Beckman Research Institute; City of Hope National Medical Center; M.D. Anderson Cancer Center; Vanderbilt University School of Medicine; New York University School of Medicine; University of Chicago; University of California, Irvine; Stanford University
Recruiting - verified January 2012
A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Condition: Colon Cancer
Intervention:
Sponsors: Agendia; Agendia
Recruiting - verified March 2012
Familial and Atypical Urothelial Cancer Registry

Conditions: Urothelial Cancer; Renal Pelvis Cancer; Ureter Cancer; Bladder Cancer
Interventions: Other: saliva sample and questionaire; Other: saliva sample, questionaire
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

Condition: Hepatocellular Carcinoma
Interventions: Drug: Brivanib; Drug: Brivanib Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: nucleic acid amplification; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: cytology specimen collection procedure; Other: flow cytometry; Procedure: biopsy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Intervention: Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collection and Storage of Blood and Tissue Samples From Patients Who Are Undergoing Surgery For Lung Cancer

Condition: Lung Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting Tumor Samples From Patients With Gynecological Tumors

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Collecting and Storing Tissue From Young Patients With Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-Small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: high performance liquid chromatography; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting Stem Cells in Patients With Waldenstrom's Macroglobulinemia

Condition: Lymphoma
Intervention: Procedure: leukapheresis
Sponsors: National Cancer Institute (NCI); Herbert Irving Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2008
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation

Conditions: Adenocarcinoma of the Prostate; Stage I Prostate Cancer; Stage II Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Interventions: Dietary Supplement: cholecalciferol; Drug: Placebo Administration
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011
The Northern-European Initiative on Colorectal Cancer

Condition: Colorectal Cancer
Intervention: Procedure: Colonoscopy
Sponsors: Norwegian Department of Health and Social Affairs; Norwegian Department of Health and Social Affairs; Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology; Erasmus Medical Centre, Dep. Of Gastroenterology, Rotterdam, The Netherlands; Landspitali University Hospital; Uppsala University Hospital, Dep. Of Surgery, Uppsala, Sweden; Karolinska Institutet; Riga Eastern Clinical University Hospital, Riga, Latvia; Memorial Sloan-Kettering Cancer Center; Harvard School of Public Health
Recruiting - verified June 2011
A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes

Conditions: Sarcoma; Leiomyosarcoma; Malignant Fibrous; Histiocytoma; Angiosarcoma
Intervention: Drug: gemcitabine and docetaxel with bevacizumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified February 2012
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer

Condition: Liver Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride; Drug: sorafenib tosylate
Sponsors: Medical University of South Carolina; Medical University of South Carolina
Recruiting - verified June 2010
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Condition: Bone Metastases
Intervention: Device: Bone Scan: F18-Fluoride PET/CT or TC-MDP
Sponsors: American College of Radiology - Image Metrix; American College of Radiology - Image Metrix; Academy of Molecular Imaging
Recruiting - verified June 2011
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Conditions: Prostate Cancer; Prostatic Neoplasms
Interventions: Drug: Panobinostat (Phase II doses); Drug: Panobinostat
Sponsors: New York University School of Medicine; New York University School of Medicine; Novartis
Recruiting - verified March 2012
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Conditions: Neuroblastoma; Bone Marrow, Sympathetic Nervous System
Intervention: Other: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011
Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer; Uterine Cancer; Vaginal Cancer; Vulvar Cancer
Intervention: Behavioral: online platform "STAR" (Symptom Tracking and Reporting for Patients)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Recruiting - verified January 2012
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant High Grade Gliomas and to Design Potential Radiation Plans

Conditions: Brain Cancer; Glioma
Intervention: Procedure: MRI and advanced MRI sequences
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine (Gemzar), docetaxel (Taxotere), and capecitabine (Xeloda)
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011
Capecitabine and Temozolomide for Neuroendocrine Cancers

Condition: Neuroendocrine Tumors
Intervention: Drug: Capecitabine and temozolomide
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011
Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar

Condition: Pancreatic Cancer Stage IVA
Interventions: Drug: Gemcitabine, docetaxel, and capecitabine; Radiation: Radiation therapy with gemcitabine
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011
Concentration and Activity of Lapatinib in Vestibular Schwannomas

Conditions: Vestibular Schwannoma; NF2; Neurofibromatosis 2; Acoustic Neuroma; Auditory Tumor
Intervention: Drug: lapatinib
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; The Children's Tumor Foundation; GlaxoSmithKline; New York University; Ohio State University; House Ear Institute
Recruiting - verified January 2012
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Conditions: Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: immunological adjuvant OPT-821; Biological: polyvalent antigen-KLH conjugate vaccine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Fludarabine, Melphalan, Total-Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Conditions: Chronic Myeloproliferative Disorders; Fanconi Anemia; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm; Paroxysmal Nocturnal Hemoglobinuria
Interventions: Biological: anti-thymocyte globulin; Biological: graft-versus-tumor induction therapy; Drug: fludarabine phosphate; Drug: melphalan; Procedure: allogeneic hematopoietic stem cell transplantation; Radiation: total-body irradiation
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: NKTR-102; Drug: irinotecan
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2012
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma

Condition: Pleural Mesothelioma
Intervention: Drug: Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011
Sunitinib in Soft Tissue Sarcoma

Condition: Sarcoma, Soft Tissue
Intervention: Drug: Sunitinib
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011
A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Condition: Non-Hodgkin's Lymphoma, Solid Cancers
Intervention: Drug: GDC-0980
Sponsors: Genentech; Genentech
Recruiting - verified May 2012
Exercise for Breast Cancer Patients (EXCAP)

Condition: Breast Cancer Related Fatigue
Interventions: Behavioral: Exercise; Behavioral: Progressive walking and resistance exercise treatment
Sponsors: University of Rochester; University of Rochester; National Cancer Institute (NCI)
Recruiting - verified November 2011
Cancer Screening and Prevention Program for High Risk Women

Conditions: Ovarian Cancer; Breast Cancer
Intervention: Other: screening
Sponsors: New York University School of Medicine; New York University School of Medicine; Lynne Cohen Foundation for Ovarian Cancer Research
Recruiting - verified November 2011
Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
A Study of of MORAb-004 in Subjects With Solid Tumors

Condition: Solid Tumor
Intervention: Drug: MORAb-004 (monoclonal antibody to TEM1)
Sponsors: Morphotek; Morphotek
Recruiting - verified November 2011
Adolescent and Young Adult Cancer Survivors: Identity Development

Condition: Cancer
Interventions: Behavioral: interview; Behavioral: Focus groups; Behavioral: Questionnaire
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Neo-Adjuvant FOLFOX for Rectal Carcinoma

Condition: Rectal Neoplasms
Interventions: Drug: FOLFOX; Procedure: total mesorectal excision (TME)
Sponsors: Beth Israel Medical Center; Beth Israel Medical Center; St. Luke's-Roosevelt Hospital Center
Recruiting - verified January 2012
An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: lapatinib; Drug: capecitabine [Xeloda]
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma

Conditions: Brain Tumors; Spinal Cord Tumors
Interventions: Drug: Temozolomide; Drug: Lapatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer

Condition: Breast Cancer
Intervention: Other: Blood draw and questionaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; New York Medical College; New York Presbyterian Hospital; Weill Medical College of Cornell University
Recruiting - verified January 2012
Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

Condition: Breast Cancer
Intervention: Drug: Dasatinib and Paclitaxel
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb
Recruiting - verified February 2012
Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
PF-00299804 As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Condition: Carcinoma, Non-small Cell
Intervention: Drug: Dacomitinib (PF-00299804)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Exercise for Prostate Cancer Patients

Condition: Prostate Cancer Related Fatigue
Intervention: Behavioral: Exercise
Sponsors: University of Rochester; University of Rochester; Department of Defense
Recruiting - verified November 2011
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Conditions: Breast Cancer; Breast Neoplasms; Breast Tumors; Cancer; Locally Recurrent and Metastatic Breast Cancer; Metastases; Metastatic Cancer; Oncology; Solid Tumors; Tumors
Interventions: Drug: AMG 386 15 mg/kg, Capecitabine and Lapatinib; Drug: AMG 386 15mg/kg, Paclitaxel and Trastuzumab; Drug: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab; Drug: AMG 386 30 mg/kg, Capecitabine and Lapatinib; Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab; Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib
Sponsors: Amgen; Amgen
Recruiting - verified March 2012
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Condition: Multiple Myeloma
Interventions: Procedure: Stem cell transplant x 1 or x 2; Drug: lenalidomide and dexamethasone
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Tufts Medical Center; Lahey Clinic
Recruiting - verified January 2012
Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors

Condition: Brain Tumors
Interventions: Drug: DC/AAT; Drug: DC/AAT-Flu; Drug: DC/KLH
Sponsors: Rockefeller University; Rockefeller University; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012
American Breast Laser Ablation Therapy Evaluation

Condition: Benign Breast Conditions; Breast Fibroadenomas
Intervention:
Sponsors: Novian Health Inc.; Novian Health Inc.
Recruiting - verified November 2011
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Chemotherapeutic Agents in Brain/Breast

Conditions: Breast Cancer; Metastatic Cancer
Interventions: Drug: capecitabine; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: lapatinib ditosylate; Drug: paclitaxel; Drug: vinorelbine ditartrate; Drug: Trastuzumab
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; Department of Defense; National Cancer Institute (NCI)
Recruiting - verified May 2012
Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Conditions: Mucosal Melanoma; Acral Melanoma; Melanoma
Intervention: Drug: Nilotinib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Massachusetts General Hospital; Novartis
Recruiting - verified October 2011
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Condition: Prostate Cancer
Interventions: Drug: Androgen Deprivation Therapy; Drug: bicalutamide; Drug: bevacizumab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Genentech; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Cancer Institute of New Jersey
Recruiting - verified February 2012
Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors

Condition: Solid Tumors
Intervention: Drug: perifosine
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Wisconsin, Madison; Duke University; Keryx / AOI Pharmaceuticals, Inc.
Recruiting - verified April 2012
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Condition: Leukemia
Intervention: Drug: Midostaurin
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer

Conditions: Prostate Cancer; Elevated Prostate Specific Antigen (PSA)
Intervention: Other: serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH); New York Presbyterian Hospital; Weill Medical College of Cornell University; State University of New York - Downstate Medical Center; New York University School of Medicine; Kings County Hospital
Recruiting - verified January 2012
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Multicenter Clinical Study of the Sonablate®500 for the Treatment of Locally Recurrent Prostate Cancer With HIFU

Condition: Recurrent Prostate Cancer
Intervention: Device: High Intensity Focused Ultrasound
Sponsors: USHIFU, LLC; USHIFU, LLC
Recruiting - verified April 2012
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Biological: Bevacizumab; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer

Condition: Esophageal Neoplasms
Intervention: Procedure: Esophagectomy
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified August 2011
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
CryoSpray Ablation (TM) GI Patient Registry

Conditions: Barrett's Esophagus With or Without Dysplasia; Squamous Dysplasia of the Esophagus; Esophageal Cancer (Any Stage)
Intervention:
Sponsors: CSA Medical, Inc.; CSA Medical, Inc.
Recruiting - verified January 2012
Airway Epithelium Gene Expression: AEGIS II

Condition: Lung Cancer
Intervention: Device: Biomarker (not used as an intervention)
Sponsors: Allegro Diagnostics, Corp.; Allegro Diagnostics, Corp.; University of Pennsylvania; Columbia University; Temple University; Indiana University; University of Alabama at Birmingham; University of Missouri-Columbia; Louisiana State University Health Sciences Center in New Orleans; University of Wisconsin, Madison; Medical University of South Carolina; National Jewish Health; Overlake Hospital Bellevue WA; Pulmonary and Allergy Associates of New Jersey; Pulmonary Associates of Arizona; William Jennings Bryan Dorn VA Medical Center; Virginia Commonwealth University; Jamaica Hospital Medical Center; North Florida/South Georgia Veterans Health System; Steward St. Elizabeth; University of California, Davis; Yale University Medical Center; The Cleveland Clinic; Johns Hopkins University
Recruiting - verified May 2012
A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors

Conditions: Gastric Cancer; Pancreatic Cancer
Intervention: Other: questionnaire, Blood specimens
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy

Conditions: Cervical Cancer; Ovarian Cancer; Uterine Cancer
Intervention: Device: LigaSure vessel sealing system
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Quality of Life in Patients With Bladder Cancer

Condition: Bladder Cancer
Intervention: Behavioral: Quality Of Life questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Albert Einstein College of Medicine of Yeshiva University
Recruiting - verified March 2012
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.

Conditions: Leukemia; Myelodysplastic Syndrome; Non-Hodgkins Lymphoma; Chronic Myelogenous Leukemia
Intervention: Other: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Condition: Prostate Cancer
Interventions: Dietary Supplement: selenomethionine; Drug: finasteride; Other: placebo
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified May 2012
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Kanglaite Injection plus gemcitabine; Drug: Gemcitabine
Sponsors: KangLaiTe USA; KangLaiTe USA
Recruiting - verified January 2012
Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery

Condition: Lung Cancer
Interventions: Drug: chemotherapy; Procedure: lymphadenectomy; Procedure: neoadjuvant therapy; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery; Procedure: thoracic surgical procedure; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

Conditions: Metastatic Castration-resistant Prostrate Cancer (mCRPC); Renal Cell Carcinoma (RCC); Metastatic Melanoma (MEL); Non-small Cell Lung Cancer (NSCLC)
Interventions: Biological: BMS-936558 (MDX-1106); Biological: BMS-936558 (MDX-1106); Biological: BMS-936558 (MDX-1106); Biological: BMS-936558 (MDX-1106); Biological: BMS-936558 (MDX-1106)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Company, Ltd.
Recruiting - verified October 2011
Multiple Ascending Dose (MDX1105-01)

Condition: Cancer, Multiple Indications
Interventions: Biological: Anti-PDL-1 antibody; Biological: Anti-PDL-1 antibody; Biological: Anti-PDL-1 antibody; Biological: Anti-PDL-1 antibody; Biological: Anti-PDL-1 antibody
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2012
Acceptance of Human Papillomavirus Vaccination in Postpartum Women

Conditions: Human Papilloma Virus; HPV; Post Partum
Intervention:
Sponsors: Columbia University; Columbia University; Merck
Recruiting - verified February 2012
Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: cryosurgery; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified May 2012
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients

Conditions: Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Non-Hodgkins Lymphoma; Sarcoma; Neuroblastoma
Intervention: Other: FDA Food Safety Guidelines
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified March 2010
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
The Sexual Health of Rectal Cancer Patients

Conditions: Rectal Cancer; Rectum
Interventions: Behavioral: questionnaires; Behavioral: CSI-SH- Cancer Survivorship Intervention
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Albert Einstein College of Medicine of Yeshiva University; Mount Sinai School of Medicine; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Recruiting - verified March 2012
Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy

Condition: Mesothelioma
Intervention: Other: Pemetrexed + Cisplatin or Carboplatin AUC=5 Pleurectomy/decortication (if feasible) Intensity Modulated Radiation Therapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Eli Lilly and Company; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Talactoferrin; Drug: Placebo
Sponsors: Agennix; Agennix
Recruiting - verified March 2012
A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

Conditions: Mixed Gliomas; Malignant Gliomas; Glioblastoma Multiforme
Interventions: Drug: XL765 (SAR245409); Drug: Temozolomide
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Condition: Metastatic Breast Cancer
Interventions: Drug: Dasatinib + Letrozole; Drug: Letrozole
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; US Oncology Research
Recruiting - verified February 2012
Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials

Conditions: Aids-related Malignancies; Lymphoma; Precancerous Condition; Sarcoma
Interventions: Genetic: polymerase chain reaction; Other: cytology specimen collection procedure; Other: histological technique; Procedure: colposcopic biopsy
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified November 2011
Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer

Conditions: Lung Cancer; Precancerous Condition; Tobacco Use Disorder
Interventions: Dietary Supplement: calcitriol; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified December 2011
A Study to Evaluate the Use of the Drug Combination Vorinostat, Niacinamide, and Etoposide in Patients With Lymphoid Malignancies That Have Reoccurred

Conditions: Hodgkin's Disease; Non-Hodgkin's Lymphoma
Interventions: Drug: Vorinostat (SAHA) and Niacinamide; Drug: Vorinostat, Niacinamide and Etoposide
Sponsors: Columbia University; Columbia University; Merck
Recruiting - verified February 2012
Oxaliplatin, Capecitabine, Cetuximab, and Radiation Therapy Followed By Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: capecitabine; Drug: oxaliplatin; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic surgical procedure; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers

Condition: Retinoblastoma
Interventions: Genetic: DNA ploidy analysis; Genetic: DNA stability analysis; Genetic: Southern blotting; Genetic: genetic linkage analysis; Genetic: loss of heterozygosity analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: environmental carcinogenesis study; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: evaluation of cancer risk factors; Procedure: mutation carrier screening
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Safety Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of Bone

Conditions: Cancer; GCT; Giant Cell Tumor of Bone; Benign GCT
Intervention: Drug: Denosumab
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
Safety and Efficacy of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Condition: Symptomatic Refractory Resistant Carcinoid Disease
Interventions: Drug: Pasireotide; Drug: Octreotide
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

Conditions: Lung Neoplasm; Carcinoma Non-small Cell Lung Cancer Stage IIIA; Carcinoma Non-small Cell Lung Cancer Stage IIIB; Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions: Biological: Lucanix™; Other: Placebo Comparator
Sponsors: NovaRx Corporation; NovaRx Corporation
Recruiting - verified April 2012
Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx

Condition: Head and Neck Cancer
Interventions: Drug: HPPH; Procedure: laser therapy
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified December 2011
Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies

Conditions: Leukemia; Myelodysplastic Syndrome
Intervention: Biological: ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI); Actinium Pharmaceuticals
Recruiting - verified January 2012
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Conditions: Hedgehog Pathway; Smoothened; Basal Cell Carcinoma (BCC); Basal Cell Nevoid Syndrome (BCNS)
Intervention: Drug: BMS-833923 (XL139)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified August 2011
ChemoFx® PRO - A Post-Market Data Collection Study

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Uterine Neoplasms; Endometrial Cancer; Vaginal Cancer; Vulvar Cancer; Cervical Cancer; Lung Cancer; Carcinoid Tumor of Lung; Sarcoma of Lung; Mesothelioma; Colorectal Cancer
Intervention:
Sponsors: Precision Therapeutics; Precision Therapeutics
Recruiting - verified June 2011
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: pemetrexed disodium; Drug: docetaxel
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer

Condition: Carcinoma, Squamous Cell
Interventions: Drug: paclitaxel poliglumex; Biological: cetuximab; Radiation: radiation therapy (IMRT or 3D-CRT)
Sponsors: State University of New York - Upstate Medical University; State University of New York - Upstate Medical University; Cell Therapeutics
Recruiting - verified April 2012
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Panitumumab Pediatric Study

Condition: Solid Tumors
Intervention: Drug: Panitumumab Treatment
Sponsors: Amgen; Amgen
Recruiting - verified July 2011
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Conditions: Bone Metastases; Multiple Myeloma
Interventions: Device: ExAblate 2000; Device: Sham
Sponsors: InSightec; InSightec
Recruiting - verified October 2011
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

Conditions: MDS; AML; Solid Tumors; Multiple Myeloma; Non-Hodgkin's Lymphoma; Hodgkin's Disease
Interventions: Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012
Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients

Condition: Abnormalities, Radiation-Induced
Intervention:
Sponsors: State University of New York - Upstate Medical University; State University of New York - Upstate Medical University; Carol M. Baldwin Breast Cancer Research Fund, Inc.
Recruiting - verified July 2011
A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)

Condition: Solid Tumors
Interventions: Drug: MK1775; Drug: gemcitabine; Drug: cisplatin; Drug: carboplatin; Drug: MK1775; Drug: MK1775; Drug: MK1775; Drug: gemcitabine; Drug: cisplatin; Drug: carboplatin
Sponsors: Merck; Merck
Recruiting - verified May 2012
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011
Breath Test for Early Detection of Lung Cancer

Condition: Lung Neoplasms
Intervention:
Sponsors: Menssana Research, Inc.; Menssana Research, Inc.
Recruiting - verified June 2011
Tissue Expander/Implant Reconstruction: A Single-Blinded, Randomized, Controlled Trial

Condition: Breast Cancer
Interventions: Procedure: Alloderm, Questionnaires; Procedure: Without ALLODERM, Questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Michigan; University of North Carolina, Chapel Hill
Recruiting - verified December 2011
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified May 2012
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.

Condition: Hematologic Neoplasms
Intervention: Drug: RO5045337
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

Conditions: Soft Tissue Sarcoma; Mesothelioma
Intervention: Drug: Azacitidine In Combination With Temozolomide
Sponsors: Columbia University; Columbia University; Schering-Plough; Celgene Corporation
Recruiting - verified October 2011
A Pilot Study of the Use of the DaVinci Robotic System for Otorhinolaryngology-Head and Neck Surgery

Condition: Head and Neck Neoplasms
Intervention: Device: robot assisted endoscopic head and neck surgery using the DaVinci Robotic Surgical System
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified July 2011
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)

Condition: Hepatocellular Carcinoma
Interventions: Drug: ThermoDox; Drug: 5% Dextrose Solution
Sponsors: Celsion; Celsion
Recruiting - verified June 2011
Laparoscopic Approach to Cervical Cancer

Condition: Cervical Cancer
Interventions: Procedure: Total Abdominal Radical Hysterectomy; Procedure: Total Laparoscopic or Robotic Radical Hysterectomy
Sponsors: Queensland Centre for Gynaecological Cancer; Queensland Centre for Gynaecological Cancer; M.D. Anderson Cancer Center
Recruiting - verified June 2011
Efficacy of Electrical Stimulation for Dysphagia in Head & Neck Cancer Patients

Condition: Dysphagia
Intervention: Device: Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)
Sponsors: Boston Medical Center; Boston Medical Center; Northwestern University; Boston University; University of Wisconsin, Madison; New York University; VA Boston Healthcare System; Lahey Clinic; Lenox Hill Hospital; Beth Israel Medical Center; Greater Baltimore Medical Center; Medical College of Wisconsin; Community Medical Center, Inc; Henry Ford Hospital; University of California, San Diego; University of California, Davis; University of Washington; Oregon Health and Science University
Recruiting - verified June 2011
Huntsman Biopsy Study

Conditions: Soft Tissue Sarcoma; Osteosarcoma
Intervention:
Sponsors: State University of New York - Upstate Medical University; State University of New York - Upstate Medical University; Huntsman Cancer Institute
Recruiting - verified August 2010
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery

Conditions: Breast Cancer; Breast Surgery; Breast Reconstruction; Breast Reduction; Breast Augmentation
Interventions: Behavioral: questionnaires; Behavioral: questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; McMaster University; University College, London; Dartmouth-Hitchcock Medical Center; University of British Columbia; Johns Hopkins University; University of Pittsburgh
Recruiting - verified January 2012
Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients

Condition: Head and Neck Cancer
Intervention: Other: F-MISO PET scan
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Quality of Life in Patients Undergoing Total Pelvic Exenteration

Conditions: Total Exenteration,; Anterior or Posterior Pelvic Exenteration; Gynecologic Malignancies; Colorectal Malignancies; Urologic Malignancies
Intervention: Behavioral: questionnaires/interviews
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Vascular CT Assessment of Structural Autograft and Allograft Healing

Condition: Bone Tumors
Intervention: Device: Cone Beam CT Scan
Sponsors: University of Rochester; University of Rochester; National Institutes of Health (NIH)
Recruiting - verified February 2012
Confocal Reflectance Microscopy of Shave-Biopsy Sites on Skin in Vivo.

Conditions: Basal Cell Carcinoma; Melanoma; Squamous Cell Carcinoma; Non-Malignant Skin Disorders
Intervention: Procedure: confocal microscopy in vivo
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Recruiting - verified March 2012
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: carboplatin; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Genetic: polymerase chain reaction; Genetic: western blotting
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified December 2011
Improving Therapeutic Outcomes in the Tongue Carcinoma Patient: Assessment of Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging

Condition: Tongue Carcinoma
Intervention: Procedure: MRI
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Rockefeller University; New York Presbyterian Hospital
Recruiting - verified April 2012
A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Conditions: Systemic Anaplastic Large-Cell Lymphoma; Neoplasms; Anaplastic Lymphoma Kinase, Human; NSCLC
Interventions: Drug: PF-02341066; Drug: Rifampin; Drug: Ketoconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012
A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy

Conditions: Cancer; Leukemia; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma
Interventions: Drug: Fludarabine, Cyclophosphamide; Procedure: Transplantation
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Conditions: CNS Cancer; Meningioma; Intracranial Hemangiopericytoma; Hemangioblastoma; Neurofibromatosis
Intervention: Drug: Sunitinib
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Dana-Farber Cancer Institute; University of Virginia; University of Pittsburgh; Pfizer
Recruiting - verified November 2011
In Vivo Confocal Microscopy of Cutaneous Neoplasms and Normal Skin

Condition: Skin Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012
Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Memorial University Medical Center
Recruiting - verified February 2012
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)

Condition: Adenomatous Polyposis Coli
Interventions: Drug: Celecoxib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Magnetic Resonance Spectroscopic Imaging of the Prostate at 3 Tesla

Conditions: Prostate Cancer; MRI
Intervention: Other: Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA

Conditions: Pediatric Cancers; Oncology
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI); Children's Oncology Group; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified February 2012
Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Lung Cancer; Melanoma; Non-Hodgkin's Lymphoma; Uterine Cancer; CORPUS UTERI,ENDOMETRIUM; LUNG; OVARY
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma

Conditions: CNS Cancer; CNS BRAIN
Intervention: Drug: temozolomide followed by high dose busulfan and thiotepa
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Calgary; Northwestern University; Northwestern Memorial Hospital; University of Wisconsin, Madison; Massachusetts General Hospital; Schering-Plough
Recruiting - verified December 2011
Anxiety in Black Men With Prostate Cancer: Validation of the Memorial Anxiety Scale for Prostate Cancer in an Sample of Black Men

Condition: Prostate Cancer
Intervention: Behavioral: questionnaires of quality of life
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University School of Medicine(VA-NYU); State University of New York - Downstate Medical Center; Kings County Hospital Center
Recruiting - verified December 2011
Early Onset and Familial Gastric Cancer Registry

Condition: Gastric Cancer
Intervention: Behavioral: questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University; Queens Health Network; USC/Norris Comprehensive Cancer Center; Shaare Zedek Medical Center; Obafemi Awolowo University Teaching Hospital; State University of New York - Downstate Medical Center
Recruiting - verified December 2011
Longitudinal Assessment of Health-Related Quality of Life in Men With Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Behavioral: Interview; Behavioral: survey instruments using Web-Based Data Collection System (WBDC) survey content
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011
A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Other: CA 125 and CT scan
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Johns Hopkins University; M.D. Anderson Cancer Center
Recruiting - verified January 2012
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome

Condition: Neuroblastoma
Intervention: Other: Tumor and Marrow Markers
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Southern Illinois University; Spanish National Cancer Center; St. Jude Children's Research Hospital; Washington University School of Medicine; University of Texas
Recruiting - verified December 2011
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract

Conditions: Esophageal Cancer; Bile Duct Neoplasms; Gastric Cancer; Liver Cancer; Melanoma; Pancreatic Cancer; Sarcoma
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Multi-Organ Screening Recommendations in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients

Conditions: Hereditary Nonpolyposis Colorectal Cancer; Colon Cancer
Interventions: Behavioral: questionnaires, telephone interview, optional tube of blood drawn; Behavioral: questionnaires, telephone interview and optional tub of blood drawn
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI); Albert Einstein College of Medicine of Yeshiva University
Recruiting - verified February 2012
Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ

Conditions: Breast Cancer; Lobular Carcinoma; Invasive Breast Cancer
Intervention: Other: Tissue specimen
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Immediate Vaginal Reconstruction After Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function

Condition: Vaginal Cancer
Intervention: Behavioral: QOL
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

Conditions: Lymphoma; Leukemia; Multiple Myeloma; Colon Cancer; Renal Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012
Dynamic Contrast Enhanced MRI (DCE-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors

Condition: Head and Neck Cancer
Intervention: Radiation: DCE-MRI, MRS
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Recruiting - verified March 2012
Men Undergoing Radical Prostatectomy

Condition: Prostate Cancer
Intervention: Other: Whole Blood Draw
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012
Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer

Condition: Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC)
Intervention: Other: Tumor core biopsy for RNA isolation
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012
Quantitative Dynamic Contrast Enhanced Breast MRI

Condition: Breast Cancer
Intervention: Other: perform dynamic contrast enhanced (DCE) MRI
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Oregon Health and Science University; DeltaPoint,Inc.
Recruiting - verified December 2011
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

Conditions: Breast Cancer; Colon Cancer; Prostate Cancer
Intervention: Genetic: PCR/PCR/LDR Strategy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Columbia University; Weill Medical College of Cornell University
Recruiting - verified November 2011
Spectroscopy With Surface Coils and Decoupling

Conditions: Adrenal Cortical Cancer; Brain Cancer; Breast Cancer; CNS Cancer; Colon Cancer; HEENT Cancer; Hodgkin's Disease; Kaposi's Sarcoma; Liver Cancer; Lung Cancer; Non-Hodgkin's Lymphoma; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Rectal Cancer; Renal Cancer; Sarcoma; Squamous Cell Carcinoma; Thyroid Cancer
Interventions: Device: Proton-decoupled 31P MRS at 1.5T; Device: 1H Spectroscopy at 1.5T and 3T
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Columbia University; University of Pennsylvania; St.George's Hospital (England); Royal Marsden NHS Foundation Trust; University Medical Center Nijmegen; Weill Medical College of Cornell University
Recruiting - verified February 2012
Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer

Condition: Bladder Cancer
Intervention: Drug: Paclitaxel, nanoparticle albumin-bound
Sponsors: Columbia University; Columbia University; Celgene Corporation
Recruiting - verified February 2012
Radiation Biodosimetry in Patients Treated With Total Body Irradiation (TBI)

Condition: Cancer
Intervention: Other: Blood Samples
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Columbia University
Recruiting - verified July 2011
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers

Conditions: Breast Neoplasms; Ovarian Neoplasms; Colonic Neoplasms; Prostatic Neoplasms; Uterine Cervical Neoplasms; Leukemia; Lymphoma, Non-Hodgkin
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012
Clinical Outcomes in Hereditary Cancer

Conditions: Breast Cancer; Pancreatic Cancer
Intervention: Other: Genotyping
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011
The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older

Condition: Prostate Cancer
Interventions: Behavioral: Questionaires; Behavioral: Questionaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI); City of Hope National Medical Center; Fordham University; Columbia University; New York University Medical Center
Recruiting - verified March 2012
Molecular Studies and Clinical Correlations in Human Prostatic Disease

Condition: Prostate Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Rockefeller University; Flinders Medical Centre; Aureon Biosciences, Inc.; University of Southern California; Gen-Probe, Incorporated; Genentech; General Electric; Purdue University; Biocept, Inc.; Duke University; Ikonysis, New Haven, CT; Array Genomics; Cold Spring Harbor Laboratory
Recruiting - verified December 2011
Clinical Significance of Germline BRCA Mutations

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
RECONSTRUCTIVE SURGERY For Head And Neck Cancer Patients

Condition: Advanced Stage Head and Neck Cancer
Intervention: Behavioral: Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Clinical and Quality of Life Outcomes After Open or Robotic-Assisted Laparoscopic Radical Prostatectomy

Conditions: Prostate Cancer; Quality of Life
Intervention: Behavioral: Quality of Life Questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; The Cleveland Clinic
Recruiting - verified December 2011
Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors

Condition: Osteosarcoma
Intervention: Biological: Tissue Procurement
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Hospital for Special Surgery, New York
Recruiting - verified October 2011
Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Bone Marrow Transplantation Patients

Condition: Neoplasms
Intervention: Other: buccal swabs and obtaining peripheral blood
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI); American Cancer Society; Montefiore Medical Center
Recruiting - verified May 2012
Ascertainment of Saliva or Blood Samples For Genetic Epidemiology Studies of Cancer and Aging

Condition: Non-cancer Affected Volunteers
Intervention: Other: Saliva or Blood samples
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Susan G. Komen Breast Cancer Foundation; Beth Abraham; Gurwin Jewish Nursing & Rehabilitation Center; Hebrew Home for the Aged; Jewish Home and Hospital Lifecare System; Margaret Tietz Center; Metropolitan Jewish Health System; Northern Services Group; Parker Jewish Institute; Lenox Hill Neighborhood House; JASA at Temple Emanuel of Parkchester Senior Center; Van Cortlandt Village Senior Center
Recruiting - verified December 2011
Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients

Condition: Colorectal Cancer
Intervention: Radiation: Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

Condition: Sarcoma
Intervention: Other: Specimen protocol
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified May 2012
Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis

Condition: Recurrent Respiratory Papillomatosis
Interventions: Drug: celebrex (celecoxib); Drug: placebo capsules
Sponsors: North Shore Long Island Jewish Health System; North Shore Long Island Jewish Health System; National Institute on Deafness and Other Communication Disorders (NIDCD)
Recruiting - verified January 2012
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Condition: Non-small Cell Lung Cancer
Intervention: Drug: Erlotinib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Genentech
Recruiting - verified March 2012
Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg

Condition: Melanoma (Skin)
Interventions: Drug: melphalan; Drug: sorafenib tosylate; Genetic: gene expression analysis; Genetic: protein expression analysis; Genetic: western blotting; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified August 2009
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
An Investigational Drug, PD 0332991, Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

Condition: Multiple Myeloma
Interventions: Drug: Bortezomib; Drug: Dexamethasone; Drug: PD 0332991
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: samarium Sm 153 lexidronam pentasodium
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cognitive Changes Associated With Breast Cancer Treatment

Conditions: Breast Cancer; Cognitive Side Effects of Cancer Treatments; Stage I, II and III A Breast Cancer
Interventions: Behavioral: Questionnaires, MRI, Comet assay and Cell senescence; Behavioral: Questionnaires, MRI, Comet assay and Cell senescence; Behavioral: Questionnaires, MRI, Comet assay and Cell senescence
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University; The City College of New York; Brigham and Women's Hospital
Recruiting - verified February 2012
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Conditions: NHL; Lymphoma, Non-Hodgkin; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Intermediate-Grade; Lymphoma, Large-Cell; Lymphoma, Low-Grade; Lymphoma, Mixed-Cell; Lymphoma, Small-Cell; Leukemia, Lymphocytic, Chronic; Leukemia, B-Cell, Chronic; Leukemia, Prolymphocytic; Leukemia, Small Lymphocytic; Lymphoma, Small Lymphocytic; Lymphoma, Lymphoplasmacytoid, CLL; Lymphoplasmacytoid Lymphoma, CLL; CLL; SLL
Intervention: Biological: veltuzumab
Sponsors: Immunomedics, Inc.; Immunomedics, Inc.
Recruiting - verified March 2012
Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma; Liver Cancer; Hepatoma
Interventions: Device: Bead Block microspheres; Other: Bead + Dox Arm
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Columbia University
Recruiting - verified March 2012
Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer

Condition: Prostate Cancer
Interventions: Dietary Supplement: calcitriol; Drug: ketoconazole; Drug: therapeutic hydrocortisone
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; Department of Defense
Recruiting - verified January 2012
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant

Conditions: Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Intervention: Biological: donor lymphocytes
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors

Condition: Brain Tumors
Intervention: Drug: temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
Sponsors: New York University School of Medicine; New York University School of Medicine; Children's Hospitals and Clinics of Minnesota; Schneider Children's Hospital
Recruiting - verified January 2012
Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Drug: HPPH
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Conditions: Gastroesophageal Junction Adenocarcinoma; Gastric Cancer
Interventions: Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin; Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Sanofi-Aventis; Roche/Genetech; City of Hope National Medical Center; Piedmont Hospital Research Institute (PHRI); Medical College of Wisconsin; Queens Health Network; Weill Medical College of Cornell University; Memorial Cancer Institute, Florida; University of Pittsburgh; Long Island Jewish Medical Center; Nebraska Cancer Specialists Methodist Estabrook Cancer Center
Recruiting - verified January 2012
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy; Procedure: videothoracoscopy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified April 2012
Randomized Controlled Trial of Group Psychotherapy Interventions for Cancer Patients

Condition: Palliative Care
Interventions: Behavioral: Meaning Centered Group Psychotherapy; Behavioral: Supportive Group Psychotherapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Fordham University
Recruiting - verified January 2012
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate

Conditions: Atypical Endometrial Hyperplasia; Endometrial Carcinoma
Intervention: Drug: Megestrol Acetate
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified March 2012
Study to Evaluate Immune Responses in Neurologically Normal Cancer Patients

Condition: Healthy
Intervention:
Sponsors: Rockefeller University; Rockefeller University
Recruiting - verified January 2012
Assessment Tool for Older Patients With Cancer

Conditions: Cognitive/Functional Effects; Psychosocial Effects of Cancer and Its Treatment; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

Conditions: Ototoxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: etoposide; Drug: sunitinib malate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified November 2011
Intracerebral Clysis in Treating Patients With Recurrent Primary Brain Tumors

Conditions: Recurrent Anaplastic Astrocytoma; Recurrent Anaplastic Oligodendroglioma; Recurrent Anaplastic Oligo-Astrocytoma; Recurrent Glioblastoma Multiforme
Intervention: Drug: Topotecan
Sponsors: Columbia University; Columbia University; National Cancer Institute (NCI); Herbert Irving Comprehensive Cancer Center
Recruiting - verified December 2011
Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Biobank For MS And Other Demyelinating Diseases

Conditions: Multiple Sclerosis; Transverse Myelitis; Neuromyelitis Optica; Acute Disseminated Encephalomyelitis; Optic Neuritis
Intervention:
Sponsors: Accelerated Cure Project for Multiple Sclerosis; Accelerated Cure Project for Multiple Sclerosis
Recruiting - verified March 2012
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified September 2011
Gliogene: Brain Tumor Linkage Study

Conditions: Brain Tumor; Glioma
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Erlotinib Prevention of Oral Cancer (EPOC)

Condition: Oral Cancer
Interventions: Drug: Erlotinib; Drug: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity

Condition: Breast Cancer
Intervention: Biological: MAB HER 2 (HERCEPTIN)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Randomized Trial of Unruptured Brain AVMs

Condition: Unruptured Brain Arteriovenous Malformation
Intervention: Procedure: invasive therapy [endovascular procedures, neurosurgery, or radiotherapy, alone or in combination]
Sponsors: Columbia University; Columbia University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified September 2011
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor

Conditions: Kidney Cancer; Metastatic Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified July 2011
Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection

Conditions: Breast Cancer; Lymphedema; Perioperative/Postoperative Complications
Interventions: Behavioral: exercise intervention; Other: educational intervention; Procedure: assessment of therapy complications; Procedure: complementary or alternative medicine procedure; Procedure: management of therapy complications; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

Condition: Kidney Neoplasms
Interventions: Drug: Sunitinib malate; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Blood Collection From Individuals With Lung Disease for Genetic Studies

Conditions: Asthma; COPD; Interstitial Lung Disease; Cystic Fibrosis; Lung Cancer
Intervention:
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified August 2011
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Conditions: Breast Cancer; Neoplasm Metastasis
Interventions: Other: Standard supportive care (packed RBC transfusion); Drug: epoetin alfa + packed RBC transfusion
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified February 2012
The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes

Condition: Paraneoplastic Syndromes
Intervention:
Sponsors: Rockefeller University; Rockefeller University
Recruiting - verified May 2012
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Condition: Breast Cancer
Intervention: Drug: Zometa® (zoledronic acid)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer

Condition: Anal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2011
Safety Study of Intracerebral Topotecan for Recurrent Brain Tumors

Condition: Brain Neoplasms, Primary Malignant
Interventions: Procedure: Convection-Enhanced Delivery; Drug: Topotecan
Sponsors: Columbia University; Columbia University
Recruiting - verified February 2012
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma

Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma
Intervention: Drug: Erlotinib
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; Genentech
Recruiting - verified March 2012
A Randomized Study of Sulindac in Oral Premalignant Lesions

Conditions: Leukoplakia, Oral; Benign Neoplasms
Interventions: Drug: sulindac; Drug: Placebo
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Amrita Institute of Sciences, AIMS, Cochin, India; Weill Medical College of Cornell University; Regional Cancer Center(RCC), Trivandrum, India; Narayana Hrudayalaya Hospitals
Recruiting - verified January 2012
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

Condition: Melanoma
Interventions: Procedure: Completion Lymphadenectomy; Procedure: Monitoring with nodal ultrasound
Sponsors: John Wayne Cancer Institute; John Wayne Cancer Institute; National Institutes of Health (NIH)
Recruiting - verified January 2012
Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation

Condition: Breast Cancer
Interventions: Genetic: mutation analysis; Other: counseling intervention
Sponsors: Georgetown University; Georgetown University; National Cancer Institute (NCI)
Recruiting - verified October 2011
Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer

Condition: Intraabdominal Cancers (Various Types)
Intervention: Biological: Implantation of cancer macrobeads in the abdominal cavity by laparoscopy
Sponsors: The Rogosin Institute; The Rogosin Institute
Recruiting - verified April 2012
Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Intervention: Drug: Selected Vegetable and Herb Mix
Sponsors: Sun Farm Corporation; Sun Farm Corporation; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified October 2011
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Condition: Bladder Cancer
Interventions: Biological: trastuzumab; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: gemcitabine hydrochloride; Drug: paricalcitol
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; Abbott
Recruiting - verified January 2012
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma

Conditions: Refractory Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: melphalan; Drug: amifostine trihydrate; Procedure: peripheral blood stem cell transplantation; Genetic: fluorescence in situ hybridization; Procedure: bone marrow ablation with stem cell support
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Yoga-Based Cancer Rehabilitation Program

Conditions: Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms
Intervention: Behavioral: Yoga
Sponsors: Albert Einstein College of Medicine of Yeshiva University; Albert Einstein College of Medicine of Yeshiva University; National Cancer Institute (NCI); The Jacob and Valeria Langeloth Foundation
Recruiting - verified February 2012
Mind-Body Program for Cancer Patients

Condition: Neoplasms
Interventions: Behavioral: Mind-Body Psychotherapy Group; Behavioral: Mind-Body Psychotherapy Group
Sponsors: Albert Einstein College of Medicine of Yeshiva University; Albert Einstein College of Medicine of Yeshiva University; American Cancer Society
Recruiting - verified February 2012
Molecular Classification of Head and Neck Tumors Using cDNA Microarray Analysis to Detect Prognosis and Response to Therapy

Condition: Head and Neck Neoplasms
Intervention:
Sponsors: Montefiore Medical Center; Montefiore Medical Center; National Institutes of Health (NIH)
Recruiting - verified June 2011
Phase III of Unilateral Neck Irradiation With Amifostine in Patients With SCC of the Head and Neck

Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Radiation: amifostine plus radiation therapy (amifostine arm); Radiation: definitive external beam radiation in the ipsilateral neck
Sponsors: Beth Israel Medical Center; Beth Israel Medical Center
Recruiting - verified January 2012
Genotoxicity Assessment for Patients Undergoing Radiation Treatment

Condition: Neoplasms
Intervention:
Sponsors: University of Rochester; University of Rochester
Recruiting - verified August 2011
A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

Condition: Sarcoma
Intervention: Drug: Trabectedin
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma

Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Prednisone
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Sanofi-Aventis
Recruiting - verified September 2011
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified June 2011
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer

Condition: Kidney Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Weill Medical College of Cornell University; National Cancer Institute (NCI)
Recruiting - verified June 2009
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation; Radiation: brachytherapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Conditions: Glioblastoma Multiforme; Glioblastoma; GBM; Grade IV Astrocytoma; Glioma; Brain Cancer; Brain Tumor
Intervention: Drug: Dendritic cell immunotherapy
Sponsors: Northwest Biotherapeutics; Northwest Biotherapeutics
Recruiting - verified May 2012
Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer - EORTC; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified December 2011
Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

Conditions: Adult Langerhans Cell Histiocytosis; Childhood Langerhans Cell Histiocytosis; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); Herbert Irving Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2007
Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Condition: Ovarian Cancer
Intervention: Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: fludarabine phosphate; Drug: melphalan; Drug: thiotepa; Radiation: total-body irradiation
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified December 2011